Advancing science across hematology. š¬ At #ash2026, we'll share a breadth of data spanning our broad malignant and classical hematology programs. Explore our expanding research: investor.regeneron.com/news-releases/news-release-detailsā¦
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. More on Wikipedia
-
Regeneron
@Regeneron
-
Regeneron
@Regeneron
The U.S. FDA has approved our medicine as the first and only siRNA therapy in generalized myasthenia gravis (#gmg), which offers a new approach for people living with this debilitating, often unpredictable disease.
Ā
Read more: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
We are pleased to share that the European Commission (EC) has approved an updated dosing regimen for our medicine across its currently approved indications in skin, lung, and cervical cancers. Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Today we presented results from our POTS (postural orthostatic tachycardia syndrome) Phase 2 trial at the American Autonomic Society annual meeting.
Ā
Read the release to learn more about our novel investigational therapy: investor.regeneron.com/news-releases/news-release-detailsā¦
Ā
#aas2026 #pots -
Regeneron
@Regeneron
We presented positive results for our investigational siRNA therapeutic in metabolic dysfunction-associated steatotic liver disease (#masld) at #aasld2026 that were also published by @NEJM.
Learn more: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
Weāre proud to be named āBest Biotechnology Productā at the International Prix Galien, and weāre grateful to @GalienFdn for the recognition. š Thank you to the scientists, patients and colleagues behind our medicine. #prixgalien2026
-
Regeneron
@Regeneron
Regeneron third quarter 2026 financial results: total revenues of $5.1B up 36% vs. Q3 2025. Full release: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Regeneron remains committed to infectious diseases preparedness, from the laboratory to the communities most affected by outbreaks. Read more about our latest efforts against EbolaĀ here: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Late breaking at #esmo26: We are presenting longer term results from our Phase 3 trial evaluating adjuvant immunotherapy for those with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
We are pleased to share that the European Medicines Agencyās CHMP has recommended approval of an alternative dosing regimen for our immunotherapy across its currently approved skin, lung, and cervical cancer indications.
Learn more: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
Today we announced positive 84-week results from a Phase 3 clinical trial investigating our therapy in adults with fibrodysplasia ossificans progressiva (FOP). Learn more about our findings at #asbmr2026: newsroom.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
At #esmo26, we'll share new oncology research across several cancers, including late-breaking data.
Together, these studies highlight the breadth of our oncology research, which spans cancer treatment to challenges beyond cancer itself.
Learn more: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
Positive preliminary results for our investigational bispecific antibody in low-grade serous #ovariancancer (#lgsoc) reinforce our vision to advance care for people with difficult-to-treat cancers.
Learn more about the late-breaking results: investor.regeneron.com/news-releases/news-release-detailsā¦
#igcs2026 -
Regeneron
@Regeneron
šŖ At #easd2026, weāre presenting new data from our obesity program showing the impact our investigational asset has on lean mass during GLP-1-induced weight loss in people living with obesity.
Learn more: newsroom.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
Today, we announced the addition of multiple next-generation, long-acting antibodies to Regeneron and @Sanofi's long-standingāÆimmunologyāÆcollaboration. Read more: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
#breakingnews: The U.S. FDA approved our medicine to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP) ā an ultra-rare genetic disorder. Read more: newsroom.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Join us in celebrating the 2026 Regeneron Prize for Creative Innovation winners ā early-career scientists honored for their bold 'dream project; proposals in biomedical research. Meet this yearās winners. š investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Today, we announced second quarter 2026 financial andĀ operatingĀ results, reflecting aĀ strongĀ quarter of pipeline progress, commercialĀ momentumĀ and continued impact forĀ peopleĀ around the world. Read more: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
We'reĀ pleased to announceĀ that regulatory submissions have been accepted for review by the U.S. FDA andĀ EMAĀ for our novel siRNA investigationalĀ medicineĀ forĀ adult patients with generalized myasthenia gravis (#gmg).
Read more: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
Great music and great science demand practice and precision, and we follow the science by letting data set the tempo. This June, our teams share new work in two major music cities.
Learn more about our latest advancements: newsroom.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
A Regeneron antibody was recommended by the @WHO for investigational use in response to the current Bundibugyo Ebola outbreak. Read more: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
The European Medicines Agency accepted for review under Accelerated Assessment the Marketing Authorization Application of our investigational gene therapy to treat biallelic OTOF variant-associated #hearingloss.āØāÆāØRead more: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Today we announced positive results from the LINKER-AL2 clinical trial investigating our bispecific therapy in second-line-plus systemic amyloid light chain #amyloidosis. Learn more ahead of the oral presentation at #asco26: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Today we announced a collaboration with Parabilis Medicines that combines Regeneronās industry-leading antibody capabilities with Parabilisā novel Helicon⢠peptide platform.
Learn more: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
Today, weāre presenting late-breaking data at Digestive Disease Week from an innovative Phase 4 study in adults with eosinophilic esophagitis, a progressive disease causing narrowing of the esophagus. Read more: newsroom.regeneron.com/news-releases/news-release-detailsā¦
CC: @sanofi #ddw2026 -
Regeneron
@Regeneron
Today, we announced our first quarter 2026 financial and operating results, detailing breakthrough innovation, strong commercial performance and continued momentum across our pipeline and portfolio.
Read more: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
Today the U.S. FDA approved our medicine ā the first and only gene therapy for genetic #hearingloss ā signaling a new era where enabling 24/7 natural hearing is now possible. We are proud to make this available for free in the U.S.
Read more: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
Our medicine forāÆcertaināÆchildren aged 2-11āÆyearsāÆliving with uncontrolled chronic spontaneous urticaria (CSU)āÆhas been approved by theāÆFDA. Read more: investor.regeneron.com/news-releases/news-release-detailsā¦
CC: @sanofi -
Regeneron
@Regeneron
Positive data from our Phase 3 trial evaluating our investigational siRNA therapeutic in generalized myasthenia gravis (#gmg) were published in @TheLancet and presented at @AANmember Annual Meeting. š§
Learn more:āÆinvestor.regeneron.com/news-releases/news-release-detailsā¦
#aan2026 -
Regeneron
@Regeneron
We are collaborating with Telix Pharmaceuticals to develop and commercialize next-generation radiopharmaceutical therapies, combining our leading discovery/development antibody platform with Telixās radiopharmaceutical expertise.
Read more: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
Our medicine is now approved in the EU for certain children aged 2 to 11 years with chronic spontaneous urticaria (CSU). Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦
CC: @sanofi -
Regeneron
@Regeneron
#breakingnews: The U.S. FDA has approved our medicine for certain #retinaldiseases as the first and only injectable anti-VEGF with dosing intervals up to 5 months following one year of successful response based on visual and anatomic outcomes. investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Our treatment has been approved as the first targeted medicine for certain adults with bullous pemphigoid (BP) in Japan. For more information: investor.regeneron.com/news-releases/news-release-detailsā¦
CC:āÆ@sanofi -
Regeneron
@Regeneron
Weāre proud to share that the European Medicines Agency's CHMP recommended to approve our medicine for the treatment of certain children aged 2 to 11 years with chronic spontaneous urticaria (CSU) in the EU. Read more here: investor.regeneron.com/news-releases/news-release-detailsā¦
CC: @sanofi -
Regeneron
@Regeneron
#breaking: The U.S. FDA has approved our medicine for the treatment of allergic fungal rhinosinusitis (AFRS) in certain people aged 6 years or older. Read more: investor.regeneron.com/news-releases/news-release-detailsā¦
CC: @sanofi -
Regeneron
@Regeneron
The U.S. FDA accepted for Priority Review the Biologics License Application for our investigational medicine for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare, devastating disease.
Read more in our press release: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
At #aaaai26, we areāÆpresenting 36 abstracts highlighting our latest advances in immunology and inflammation, including first-time Phase 3 presentations in cat and birch allergy. Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Weāre pleased to present new data from our ophthalmology portfolio and pipeline at the upcoming Angiogenesis, Exudation, and Degeneration 2026 annual meeting. šļø Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
We reported fourth quarter and full-year 2025 financial and operating results today, reflecting strong financial performance and continued advances across our clinical pipeline. Read more: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
#breaking: Japanās Ministry of Health, Labour,āÆand Welfare has approved our medicine for the treatment of certain children aged 6 to 11 years in asthma. Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦
CC: @sanofi -
Regeneron
@Regeneron
Today at #ash25 we presented new data investigating our bispecific therapy in newly diagnosed #multiplemyeloma. Learn more about the latest results.
Read more: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
#breakingnews: Weāre excited to collaborate with @TesseraTx to combine our strengths in genetics and genetic medicines with Tesseraās Gene Writing⢠genome engineering technology.
-
Regeneron
@Regeneron
WeāreāÆpleased to share that the EuropeanāÆCommissionāÆhas approved our medicine for the treatment of #chronicspontaneousurticariaāÆ(CSU) in certaināÆadults and adolescents agedāÆ12+āÆin the EU.
CC: @Sanofi -
Regeneron
@Regeneron
We are pleased to announce that the U.S. FDA has approved our medicine for the treatment of macular edema following retinal vein occlusion (RVO), and a monthly dosing option in all approved indications.
-
Regeneron
@Regeneron
#breakingnews: The European Commission (EC) has approved our medicine as an adjuvant treatment for adults with cutaneous squamous cell carcinoma (#cscc) with high risk of disease recurrence after surgery and radiation.
-
Regeneron
@Regeneron
At #ash25, we're presenting new and updated data from our hematology portfolio and pipeline. Learn more about how this will highlight the next wave of potential novel approaches across a range of blood cancers and disorders.
-
Regeneron
@Regeneron
Phase 2 data on our novel investigational factor XI antibodies were published in @TheLancet and presented at the @American_Heart Scientific Sessions. Read more: investor.regeneron.com/news-releases/news-release-detailsā¦
#aha25 -
Regeneron
@Regeneron
At #acaai25, weāre presenting results from our Phase 3 trial in allergic fungal rhinosinusitis (AFRS) in people aged 6 and older. These pivotal data also support the sBLA that was recently accepted for Priority Review by the FDA. Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦
CC: @sanofi -
Regeneron
@Regeneron
Weāre honored to have been recognized by @GalienFdn for our medicine. This recognition highlights our commitment to innovative solutions that transform patients' lives. #prixgalienāÆLearn more: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
We reported third quarter 2025 financial and operating results today, demonstrating solid financial performance and continued advances in our pipeline. Read more here investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
#breaking: The CHMP has recommended EU approval of our medicine for the adjuvant treatment of cutaneous squamous cell carcinoma (#cscc) with a high risk of disease recurrence after surgery and radiation.
Read more: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
With ESMO right around the corner, we look forward to sharing updates across our diverse oncology pipeline, including data from our trial in high-risk cutaneous squamous cell carcinoma #cscc.
Learn more about our #esmo25 data: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron reposted
Regeneron Genetics Center
@RegeneronDNA
At the forefront of multi-omics, our scientists are unveiling discoveries in rare variants, cancer risk & cardiometabolic insights. Explore our latest research through posters & platform presentations all week. #ashg25
-
Regeneron
@Regeneron
Latest results from our pivotal CHORD trial for our investigational gene therapy for profound genetic hearing loss were simultaneously published by @NEJM and presented at #aaohnsf2025.
-
Regeneron
@Regeneron
We are covering air freight for @AfyaFoundationāsāÆdelivery of 40+ pallets of PPE to protect healthcare workers in the DRC. PPE is critical to prevent health system collapse during the #ebola outbreak. This follows our donation of up to 500 monoclonal antibody doses to @WHO.
-
Regeneron
@Regeneron
#breakingnews: The U.S. FDA has approved our medicine as an adjuvant treatment for adults with cutaneous squamous cell carcinoma (#cscc) with high risk of recurrence after surgery and radiation. Learn more about this approvalās potential impact: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
#breakingnews: The U.S. FDA approved our medicine to treat children aged one to less than five years with #hofh, an ultra-rare inherited condition that results in extremely high levels of LDL-C.
Learn more: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
The CHMP recommended approval of our investigational medicine for certain adults and adolescents in the EU with #chronicspontaneousurticaria (CSU).āÆ
CC: @Sanofi -
Regeneron
@Regeneron
We are donating up to 500 doses of our Ebola treatment to the @WHO and rushing doses to the DRC to help with the current outbreak. We are committed to breaking down barriers to global health access. investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
At #erscongress, weāre sharing more than 20 abstracts across #copd, #asthma and #crswnp, reinforcing our leadership in respiratory disease and continued commitment to advancing science. Learn more about the data.
CC: @Sanofi -
Regeneron
@Regeneron
Today at #easd2025, we announced results from our Phase 2 trial investigating the addition of our antibodies to a GLP-1 receptor agonist to assess its impact on quality of weight loss.āÆ
Learn more: newsroom.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
#breakingnews: Today we announced results from our Phase 3 trial in fibrodysplasia ossificans progressiva (FOP), an ultra-rare, devastating bone disease.
Read more in our press release: www.globenewswire.com/news-release/2025/09/17/3151506/0/e⦠-
Regeneron
@Regeneron
At #wclc25, weāre presenting late-breaking five-year data of our immunotherapy combination treatment in advanced non-small cell lung cancer (#nsclc). Learn more about results from this trial: newsroom.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Positive results from two separate Phase 3 trials for patients with cat and birch allergies were announced today and will support the further development of Phase 3 programs. Learn more about the data.
-
Regeneron
@Regeneron
We announced data from our positive Phase 3 trial in generalized #myastheniagravis (#gmg). Our research efforts underscore the potential of our pioneering approach using siRNA, which may offer a new type of treatment option for those suffering with this disease.
-
Regeneron
@Regeneron
Today we announced that the U.S. FDA has extended the review periods for two regulatory applications for our medicine for certain retinal diseases. Learn more about this update here.
-
Regeneron
@Regeneron
Congrats to the 2025 STEM Action Grant winners! Learn more about these organizationsš
Society for Science
@Society4Science
We're excited to announce the recipients of this year's STEM Action Grants. Congratulations to these 57 high-impact organizations! www.societyforscience.org/blog/2025-stem-action-grantees/
-
Regeneron
@Regeneron
Today, we announced our second quarter 2025 financial and operating results, highlighting how weāre pushing the boundaries of science to transform lives. Read more here investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
The FDA granted accelerated approval for our medicine to treat relapsed/refractory #multiplemyeloma after at least four prior lines of therapy. This milestone reflects our relentless commitment to make a meaningful impact in the lives of people living with multiple myeloma.
-
Regeneron
@Regeneron
#breaking: The U.S. FDA approved our medicine for #bullouspemphigoid (BP). Learn what this approval means for adults living with BP, a chronic skin disease.āÆ
CC: @Sanofi -
Regeneron
@Regeneron
Weāre unveiling new Phase 4 data from a head-to-head trial in patients with chronic rhinosinusitis with nasal polyps (#crswnp) and coexisting asthma at #eaaci2025.
CC: @Sanofi -
Regeneron
@Regeneron
Today, we presented results from our Phase 4 trial in patients with atopic dermatitis and skin of color at #rad2025. Learn more about our data.āÆāÆāÆ
CC: @Sanofi -
Regeneron
@Regeneron
Announcing an in-licensing agreement for an investigational, novel dual GLP-1/GIP receptor agonist that will enable synergy and flexibility across our broad pipeline of obesity and metabolic programs focused on improved quality of weight loss, co-morbidities and long-term health.
-
Regeneron
@Regeneron
Today, we shared interim results from our ongoing Phase 2 trial investigating the ability of our investigational treatments to improve the quality of weight loss when added to GLP-1 treatment. Read more here. investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
At #asco25, we presented detailed results from our Phase 3 trial investigating our immunotherapy as adjuvant treatment in high-risk #cscc, also published in @NEJM.
Read more here: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
At Regeneron, we strive to translate science into medicine for people impacted by cancer around the world. Hear from two of our leaders, Justin Holko and Txema Sanz, about how weāre expanding our global presence with this goal in mind. Watch the full video.
-
Regeneron
@Regeneron
Weāre announcing results from two Phase 3 trials for our investigational #copd medicine, a complex chronic respiratory disease. Learn more about the data ⤵ļø
cc: @Sanofi -
Regeneron
@Regeneron
At #asco25, weāre presenting research exploring investigational combinations in earlier lines of treatment for relapsed/refractory (R/R) #multiplemyeloma (MM). Learn more about our results in this difficult-to-treat #bloodcancer. investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Yesterday we announced our plans to acquire @23andMe. Weāre excited to strengthen our leadership in genetics-guided research and prioritize the privacy, security and ethical use of this data.
For those just getting to know Regeneron, hereās more about who we are: -
Regeneron
@Regeneron
š£Today we announced that we intend to acquire @23andMe with plans to maintain their consumer genetics business and advance our shared goal of improving human health and wellness. investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Today, a federal jury found that Amgenās anticompetitive activities prevented Regeneron from competing on a level playing field and unfairly denied patients access to its PCSK9 treatment. This verdict is critical to protecting biotech innovation and patient access to treatments.
-
Regeneron
@Regeneron
At #asco25, weāll be sharing new insights and updates from our oncology and hematology research, including the latest investigational data from key skin and blood cancer programs. Click through below and read our press release: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
š£āÆAt #ats2025, the data weāre presenting have one shared goal: advance the science in respiratory diseases like #copd and #asthma in a broad population of patients. Learn more about the latest scientific innovations weāll shareāÆā¬ļøāÆ
CC: @Sanofi -
Regeneron
@Regeneron
In 2024, we saw significant progress across our pipeline and portfolio. Hear from our co-founders, Len Schleifer and George Yancopoulos, as they reflect on last yearās progress, and visit our Year-in-Review (for investor audiences) to learn more: investor.regeneron.com/yearinreview
-
Regeneron
@Regeneron
Today, we announced our first quarter 2025 financial and operating results, detailing continued momentum across our commercial portfolio and investigational medicines. Read more investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
The European Commission has approved our medicine to treat relapsed/refractory #multiplemyeloma after at least three prior therapies. This is our second approved blood cancer medicine, reinforcing our commitment to transforming cancer care for those who need it most.
-
Regeneron
@Regeneron
Next week at #arvo2025, weāre presenting our latest research in #ophthalmology, including early insights on the real-world impact of our medicine for certain retinal diseases. Learn more about our presentations here: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Weāre proud of our pioneering advancements in #ophthalmology and collaborative approach to supporting the #retinal community. Learn more about our deep-rooted history and approach to scientific innovation in our new Eye on the Experts video series: www.regeneron.com/stories/eye-on-the-experts
-
Regeneron
@Regeneron
š£āÆWeāre announcing a new agreement with @FujifilmDiosyn in North Carolina for the manufacturing of our industry-leading biologic medicines, bringing our ongoing investments in the U.S. to more than $7B.āÆ
Read more here investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
Sharing an update on our supplemental Biologics License Application in ophthalmology. Read more here: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Exciting news! Our medicine for #chronicspontaneousurticaria (CSU) is now FDA-approved. This helps fulfill an unmet need for the more than 300,000 eligible people living with this condition in the U.S.
CC: @Sanofi -
Regeneron
@Regeneron
The U.S. FDA accepted for Priority Review our application to expand indications and dosing options for our medicine for certain #retinaldiseases.
More here: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
Regeneron CEO Len Schleifer on @CNBC: The biotech/pharma sector should be seen as the "health defense industry" vital for global wellbeing. To sustain innovation, it needs proper support.
cnb.cx/4iQSkfV -
Regeneron
@Regeneron
This morning our CEO Dr. Len Schleifer joined CNBCās Squawk Box to discuss American biotech innovation, potential pharma tariffs and ways to ensure patients have access to important new medicines.
Squawk Box
@SquawkCNBC
āWe supply the solutions for what people need when there are pandemics,ā says $REGN CEO Leonard Schleifer on the biotech industry. www.cnbc.com/video/2025/04/01/regeneron-ceo-leonard-schleā¦
-
Regeneron
@Regeneron
The Ministry of Health, Labor and Welfare in Japan has approved our medicine for adults with uncontrolled #copd, a first-of-its-kind treatment for this progressive lung disease. Our medicine is now approved in more than 45 countries for this population. Learn more.
CC: @Sanofi -
Regeneron
@Regeneron
We shared late-breaking data from a pivotal trial in adults with bullous pemphigoid at #aad2025 today. Find out more about the results.
CC: @Sanofi -
Regeneron
@Regeneron
Weāre sharing data at #aad2025 from our latest research on #atopicdermatitis, #prurigonodularis, #bullouspemphigoid and #chronicspontaneousurticaria.
CC: @Sanofi -
Regeneron
@Regeneron
The CHMP recommended EU approval of our investigational medicine to treat adults with relapsed/refractory multiple myeloma after at least three prior therapies.
-
Regeneron
@Regeneron
The U.S. FDA accepted the resubmission of our application for our investigational medicine in relapsed/refractory follicular lymphoma, after two or more lines of systemic therapy.
-
Regeneron
@Regeneron
Weāre presenting positive data from our trial evaluating an investigational gene therapy in children with profound hearing loss due to variants of the otoferlin gene at #aro2025. Learn more about the findings presented at #aro.
-
Regeneron
@Regeneron
As part of a partnership with @WSJCustom, our President and CSO George Yancopoulos sat down to share how his need to question everything grew into a philosophy that drives Regeneron today. Read more: partners.wsj.com/regeneron/the-drive-to-radically-innovatā¦
-
Regeneron
@Regeneron
At #aro2025 weāll join the auditory scientific community to share our latest research in genetic forms of hearing loss. Learn how weāre harnessing the potential of genetic medicines research and cutting-edge technologies to drive progress in the audiology field.
This media couldn't be displayed. See it on the original post. -
Regeneron
@Regeneron
The U.S. FDA accepted for priority review our application for an investigational medicine for bullous pemphigoid (BP), a chronic relapsing disease characterized by intense itch and blisters, reddening of the skin and painful lesions.āÆāÆ
CC @Sanofi -
Regeneron
@Regeneron
The U.S. FDA accepted the resubmission of our application for our investigational medicine for relapsed/refractory multiple myeloma after at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to last line of therapy.
-
Regeneron
@Regeneron
Today at the Angiogenesis, Exudation, and Degeneration 2025 annual meeting, we shared the first presentation of data from our Phase 3 trial in patients with #retinalveinocclusion.
Read more here: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
Weāre pleased to present positive three-year data from an extension study of our Phase 3 trial in patients with wet age-related macular degeneration at the Angiogenesis, Exudation, and Degeneration 2025 annual meeting.
Learn more: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
Today, we announced our fourth quarter and full year 2024 financial and operating results, with 10% revenue growth reflecting another year of strong performance. We also shared highlights from our pipeline which has the potential to transform lives for years to come. Read more:
-
Regeneron reposted
Society for Science
@Society4Science
We're excited to announce the top 40 finalists in the 2025 @Regeneron Science Talent Search! #regeneronsts www.societyforscience.org/regeneron-sts/2025-finalists/
-
Regeneron
@Regeneron
Today at the annual J.P. Morgan Healthcare Conference, weāll share our latest progress and pipeline highlights that position us strongly for continued growth. Read more here:
#jpm2025 -
Regeneron
@Regeneron
We are excited to share the first-ever positive interim data for adjuvant immunotherapy in high-risk #cscc, a form of non-melanoma #skincancer. Read more about the Phase 3 trial results in this investigational indication.
-
Regeneron
@Regeneron
We are pleased to share our clinical program in thrombosis is moving to Phase 3 clinical trials.
-
Regeneron
@Regeneron
We are pleased to share positive topline results from our Phase 3 trial in retinal vein occlusion, a serious #retinaldisease that affects over 28 million people worldwide. Explore our latest research here: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Today at #ash24 weāre presenting new data across several types of lymphoma and in earlier lines of treatment, reflecting our ongoing commitment to advancing research for difficult-to-treat blood cancers.
-
Regeneron
@Regeneron
Weāre sharing our latest advancements in hematology at #ash24, including data from a head-to head exploratory cohort of a Phase 3 trial in paroxysmal nocturnal hemoglobinuria.
-
Regeneron
@Regeneron
The U.S. FDA accepted the resubmission of our application for our investigational medicine for chronic spontaneous urticaria (CSU), a disease that causes sudden, recurring and debilitating hives and itch. CC: @Sanofi
-
Regeneron
@Regeneron
At #ash2024, weāre presenting data from our pipeline consisting of multiple modalities and spanning 10 types of blood cancers & disorders. Hear from Andres Sirulnik on how our data reflects our vision to advance research for #hematology patients.
-
Regeneron
@Regeneron
The European Commission has approved our medicine for certain children aged 1-11 years with eosinophilic esophagitis (#eoe).
CC: @Sanofi -
Regeneron
@Regeneron
Today, we announced our Q3 earnings, marking another strong financial quarter for Regeneron. Our robust performance reflects the impact of our medicines and the dedication of our talented team, who are committed to our mission and making a positive difference in the world.
-
Regeneron
@Regeneron
Late-breaking results from our confirmatory Phase 3 trial in chronic spontaneous urticaria (CSU) are being presented at #acaai24. CSU is a chronic inflammatory skin disease driven in part by type 2 inflammation. CC: @Sanofi
-
Regeneron
@Regeneron
Today we're presenting our latest research on our investigational gene therapy for otoferlin-related hearing loss atāÆ@ESGCT. Learn more about our approach to advancing gene therapy research to potentially address the underlying causes of genetic hearing loss. #esgct2024
-
Regeneron
@Regeneron
Building on years of research in certain #retinaldiseases, we are presenting new longer-term data in DME from our pivotal Phase 3 trial at the upcoming American Academy of Ophthalmology annual meeting. Learn about the data we're sharing at #aao2024:
-
Regeneron
@Regeneron
Today at @AAOHNS weāre sharing data on our investigational gene therapy for otoferlin-related hearing loss. Weāre committed to advancing gene therapy research as we investigate approaches that aim to address the root cause of genetic hearing loss. #otomtg24
-
Regeneron
@Regeneron
This week, our team is attending the @AAOHNS 2024 Annual Meeting. Weāre dedicated to advancing auditory research through pioneering efforts in genetic medicines as we aim to make a meaningful impact on people living with hearing disorders. #otomtg24
-
Regeneron
@Regeneron
#asbmr2024 starts today, and weāre excited to share our new research to advance the scientific understanding of fibrodysplasia ossificans progressiva (FOP). Connect with us at booth 315.
-
Regeneron
@Regeneron
#breakingnews: The U.S. FDA approved our medicine for adults with inadequately controlled #copd and an eosinophilic phenotype. COPD is a respiratory disease that can damage the lungs and cause progressive lung function decline. @Sanofi
-
Regeneron
@Regeneron
Our medicine is now the first of its kind approved for adults with uncontrolled #copd in China, where COPD is one of the most common chronic respiratory diseases in the country. Read more about the news.
CC: @Sanofi -
Regeneron
@Regeneron
The CHMP recommended the approval of our medicine for certain children as young as 1 year with eosinophilic esophagitis (#eoe) in Europe. CC: @Sanofi
-
Regeneron
@Regeneron
The U.S. FDA approves an age expansion of our medicine to adolescents with chronic rhinosinusitis with nasal polyps (CRSwNP). CRSwNP is a chronic disease of the upper airway, driven in part by type 2 inflammation.
CC: @SanofiUS -
Regeneron
@Regeneron
While cancer treatment has come a long way over the last 10 years, thereās still so much more to be done. Hear from Justin Holko about how we are striving to usher in a new era of care for people living with cancer around the world. #esmo24 #wclc24
-
Regeneron
@Regeneron
Weāre sharing positive results from a Phase 3 trial of our investigational medicine in certain patients with uncontrolled chronic spontaneous urticaria (CSU), a disease characterized by sudden and debilitating hives and persistent itch.
CC: @Sanofi -
Regeneron
@Regeneron
Weāre announcing data for our investigational medicine for adults with chronic skin diseases characterized by itch.
CC: @Sanofi -
Regeneron
@Regeneron
Today at #wclc24, we presented late-breaking results of the pivotal Phase 3 trial of our immunotherapy in advanced #nsclc, reflecting results at five years. Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Weāre presenting data from our oncology portfolio at #wclc24 and #esmo2024, demonstrating our commitment to transforming care for people living with difficult-to-treat cancers. Learn more about our research progress in advancing differentiated and novel combination approaches.
-
Regeneron
@Regeneron
Weāre presenting 20 abstracts featuring new data in #copd and #asthma at #erscongress. We are constantly working to advance the science on inflammatory respiratory diseases. Learn more ā¬ļø
CC: @Sanofi -
Regeneron
@Regeneron
The European Commission has approved our first blood cancer medicine for the treatment of relapsed/refractory (R/R) follicular lymphoma or R/R diffuse large B-cell lymphoma, after two or more lines of systemic therapy.
-
Regeneron
@Regeneron
Sharing a regulatory update on our investigational medicine in relapsed/refractory multiple myeloma.
-
Regeneron
@Regeneron
Today, we announced strong Q2 earnings thanks to our committed team around the globe. Heading into 2H 2024, we take pride in the expanding impact of our medicines, our thriving pipeline, and exciting technologies that sustain our approach to drug development and manufacturing.
-
Regeneron
@Regeneron
The European Commission has approved our medicine as the first-of-its-kind for adults living with uncontrolled #copd, who have not seen new treatment approaches in more than a decade. CC: @Sanofi
-
Regeneron
@Regeneron
The CHMP recommended EU approval of our investigational medicine to treat relapsed/refractory (R/R) follicular lymphoma or R/R diffuse large B-cell lymphoma.
-
Regeneron
@Regeneron
Today, @NEJM has published results from our Phase 3 trial in children aged 1 to 11 years living with eosinophilic esophagitis (#eoe), a chronic, progressive disease with underlying type 2 inflammation impacting the esophagus. Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦
CC: @Sanofi -
Regeneron
@Regeneron
At #eha2024 weāre presenting updated data in relapsed/refractory multiple myeloma, which was also simultaneously published in @JCO_ASCO. Read more.
-
Regeneron
@Regeneron
Leveraging our deep expertise in biology & underlying disease, we're thrilled to showcase our diverse research strategies across a spectrum of hematological conditions at #eha2024. Hear from Andres Sirulnik on what the future of #hematology research looks like.
-
Regeneron
@Regeneron
This weekend, NORD (@RareDiseases) held their annual #rareimpactawards to recognize leaders who improve the lives of people living with rare diseases. We were proud to be named one of the 2024 Industry Innovation Award honorees for our work in CHAPLE disease.
-
Regeneron
@Regeneron
Weāre excited to be joining the endocrinology community at #endo2024. Visit our booth, number 1133, to meet our colleagues and learn about our scientific research in endocrinology and rare disease.
-
Regeneron
@Regeneron
The CHMP recommended the approval of our medicine for certain adults with uncontrolled #copd in the European Union. CC: @Sanofi
-
Regeneron
@Regeneron
Sharing an update on the FDA priority review of our investigational medicine for certain COPD patients. investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Weāre presenting new investigational data in advanced solid tumors at #asco2024. These results are the latest in a growing body of evidence supporting our diverse set of therapeutic approaches to treat a range of difficult-to-treat cancers.
Read more: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
Late-breaking results from our replicate Phase 3 trial in COPD with @Sanofi were presented at #ats2024 and published in @NEJM.
Learn more: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron reposted
Society for Science
@Society4Science
Watch the 2024 #regeneronisef Grand Awards Ceremony now: www.youtube.com/live/Efq02674mXY
-
Regeneron
@Regeneron
We're excited to return to #ats2024 with @Sanofi and share our latest advancements in #copd and #asthma, including 17 new abstracts. Learn more about our commitment to improving outcomes for people living with these serious respiratory diseases: www.abstractsonline.com/pp8/
-
Regeneron
@Regeneron
The application for our medicine for chronic rhinosinusitis with nasal polyposis (CRSwNP) in adolescents has been accepted for Priority Review by the U.S. FDA. CRSwNP can lead to nasal congestion and loss of smell. CC: @SanofiUS Read more:
-
Regeneron
@Regeneron
Today at @ASGCTherapy weāre sharing positive new data on our investigational gene therapy for otoferlin-related deafness. Learn more about these results and the progress being made in our gene therapy auditory program. #asgct2024
-
Regeneron
@Regeneron
Today we announced Q1 2024 earnings. Our year is starting strong, with solid financial results and pipeline progress. Thank you to our colleagues who make our success possible.
-
Regeneron
@Regeneron
We congratulate our own David Glass, VP of Research and Postdoctoral Program Chair, who was elected as a member of @theNASciences. This recognition highlights his distinguished research in mechanisms of skeletal muscle atrophy and hypertrophy. We're proud of David and his team!
National Academy of Sciences
@theNASciences
We are thrilled to announce the election of 120 members and 24 international members to the National Academy of Sciences in recognition of their distinguished and continued achievements in original research.
Congratulations to our new #nasmembers and welcome to the Academy! -
Regeneron
@Regeneron
2023 was a big year for us. What made it so special? Hear our co-Founders, Len Schleifer and George Yancopoulos, reflect on our progress, and explore more in our Year in Review (for investor audiences): yearinreview.regeneron.com
-
Regeneron
@Regeneron
Weāre announcing a new collaboration with @mammothbiosci that pairs their ultracompact CRISPR editing systems with our innovative delivery technologies, expanding our targeted gene editing abilities across multiple tissue and cell types. Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Weāre presenting new and updated data from our broad oncology and hematology pipeline at #asco2024. Learn more about our presentations, which feature our novel investigational research approaches here: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Next week at @ASGCTherapy we will share data and insights into our progress in genetic medicines and our gene therapy auditory program. #asgct2024
-
Regeneron
@Regeneron
At #aacr24, weāre presenting data from our pivotal trial in relapsed/refractory multiple myeloma. Read about our latest findings.
-
Regeneron
@Regeneron
As part of our commitment to ongoing research in advanced non-small cell lung cancer (NSCLC), weāll be at #aacr24 sharing insights on the potential use of machine learning and real-world data to predict results of a key efficacy endpoint.
-
Regeneron
@Regeneron
Sharing a regulatory update on our investigational medicine for two subtypes of B-cell non-Hodgkin lymphoma.
-
Regeneron
@Regeneron
We are proud to announce the U.S. FDA approval of an age expansion treatment for heterozygous hypercholesterolemia (HeFH). This provides a new option for certain people living with this rare, inherited disorder that causes high levels of bad cholesterol. Read more.
-
Regeneron
@Regeneron
At #aad2024, weāre on the ground sharing the latest research across 26 abstracts and 8 oral presentations, highlighting data across several dermatologic conditions.
Learn more now at: www.aad.org/member/meetings-education -
Regeneron
@Regeneron
The U.S. FDA accepted for priority review the application for our investigational medicine for COPD, a serious, debilitating disease that has not seen new treatment approaches in more than a decade.
CC: @SanofiUS -
Regeneron
@Regeneron
The U.S. Food and Drug Administration (FDA) has accepted our Biologics License Application, granting Priority Review, for our investigational medicine in relapsed/refractory multiple myeloma that has progressed after at least three prior therapies.
-
Regeneron
@Regeneron
The Ministry of Health, Labor and Welfare in Japan has approved medicine for chronic spontaneous urticaria (CSU), providing a new option for certain patients struggling to manage this debilitating skin disease. @Sanofi
-
Regeneron
@Regeneron
We're committed to pushing the boundaries of science in the auditory space to help people living with hearing loss. Our pioneering genetic medicines research and technologies have the opportunity to accelerate potential treatments for hearing disorders. #aro
-
Regeneron
@Regeneron
Today at #aro, we presented updated results from the first patient dosed in our Phase 1/2 CHORD trial. These early results offer insight into the potential of gene therapy for the treatment of otoferlin-related and other genetic hearing loss. investor.regeneron.com/static-files/7dfdabe2-05d1-4145-b5ā¦
-
Regeneron
@Regeneron
Today weāre grateful to our 13,000 colleagues around the world for helping us achieve another strong quarter and full year of 2023. Weāre proud of our scientific advancements, commercial strength of our diversified portfolio and our growing impact for patients.
-
Regeneron
@Regeneron
The European Medicines Agency (EMA) accepted for review the Marketing Authorization Application for our investigational bispecific antibody to treat people living with relapsed/refractory multiple myeloma who have progressed after at least three prior lines of therapy.
-
Regeneron
@Regeneron
Today we announced the formation of Regeneron Cell Medicines with the acquisition of @2Seventybio's pipeline of investigational immune cell therapies. This new R&D unit within Regeneron will advance cell therapies and combination approaches to address cancer and other diseases.
-
Regeneron
@Regeneron
Breaking news: The @US_FDA approved an age expansion for eosinophilic esophagitis (#eoe) medicine to treat more people living with the disease. @SanofiUS
-
Regeneron
@Regeneron
A new survey conducted with @CancerResearch found that U.S. oncologists feel there are still considerable gaps in the research and treatment of advanced non-small cell lung cancer (#nsclc), despite recent advancements in the space. Click below to learn more.
-
Regeneron
@Regeneron
The U.S. FDA has updated the label for our atopic dermatitis medicine, adding safety and efficacy data specifically for patients with moderate-to-severe hand and foot involvement, a particularly difficult-to-treat subset of the disease. @SanofiUS
-
Regeneron
@Regeneron
We believe understanding core biology holds the key to answering fundamental truths about serious diseases. Our latest research explores a key driver of allergies and is the cover feature in Science Translational Medicine.
-
Regeneron
@Regeneron
At #ash23, we presented new data in R/R FL, including patient-reported outcomes, underscoring our commitment to progress new treatment options for patients with blood cancer. Learn more at the link below.
-
Regeneron
@Regeneron
Today at #ash23, we presented new research in R/R DLBCL including updated data from our pivotal trial. Learn more at the link below.
-
Regeneron
@Regeneron
Visit us at #ash23 (booth 633) to discover how our team is striving to make a big impact through our efforts in hematology ā because we know that for patients living with these difficult-to-treat blood cancers and disorders, every moment matters. www.regeneron.com/hematology
This media couldn't be displayed. See it on the original post. -
Regeneron
@Regeneron
People living with multiple myeloma may experience cycles of relapse and remission. Click to read more about todayās news on the latest results from our pivotal trial in R/R MM.
-
Regeneron
@Regeneron
At #esmoimmuno23, we are presenting new and late-breaking data on combination therapies in recurrent ovarian cancer, early-stage hepatocellular carcinoma and advanced non-small cell lung cancer. Learn more.
-
Regeneron
@Regeneron
#breaking: Our mission is to always push the boundaries of science to help people with serious diseases. And with @Sanofi, weāre doing just that for those living with moderate-to-severe #copd. Read more about todayās news and what it may mean for patients: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Weāre helping to build a brighter future for STEM. Today, we are proud to announce our renewed sponsorship of #regeneronisef, a program of @Society4Science, and the world's largest high school STEM competition. Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦
This media couldn't be displayed. See it on the original post. -
Regeneron
@Regeneron
Weāre sharing new and updated data from our investigational #hematology pipeline at #ash23. With 19 abstracts, these presentations showcase the diversity of approaches and dedication to leading-edge research in blood cancers and blood disorders.
-
Regeneron
@Regeneron
Today we celebrate the contributions of our colleagues who helped us achieve another quarter of strong growth. Q3 2023 was marked by the addition of two new FDA-approved medicines and pipeline advancements.
-
Regeneron
@Regeneron
#newsupdate: Learn more about our presentations at #aao2023 highlighting long-term data and subgroup analyses from our pivotal clinical trial program evaluating our medicine in wet age-related macular degeneration and diabetic macular edema: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
We announced positive results from the first patient dosed in the Phase 1/2 CHORD trial, evaluating our investigational gene therapy in children with genetic hearing loss due to mutations of the otoferlin gene. Read more at the link below.
-
Regeneron
@Regeneron
#esmo2023: Happening now on @endpts, Israel Lowy and Arsalan Arif discuss the shift in cancer treatments over the past decade and how these advancements are shaping our approach to research and development. Click here to watch live: endpoints.studio/events/
-
Regeneron
@Regeneron
Together with @SanofiUS, we are presenting late-breaking results from our Phase 3 trial evaluating an investigational treatment option for children aged 1-11 with eosinophilic esophagitis (#eoe) at this yearās #acg2023. Learn more.
-
Regeneron
@Regeneron
At #acg2023, weāre sharing 7 abstracts of the latest results from our research in #eosinophilicesophagitis (EoE). EoE can make eating painful and difficult, and weāre committed to helping those affected by this disease.
-
Regeneron
@Regeneron
Today at #esmo23, we shared one-year follow-up data from a Phase 2 trial in neoadjuvant resectable #cscc, a form of non-melanoma skin cancer. Learn more at the link below.
-
Regeneron
@Regeneron
We provided an update on our supplemental Biologics License Application in chronic spontaneous urticaria. Read more here:
-
Regeneron
@Regeneron
At #esmo23 later this week, we look forward to sharing new investigational data from our #oncology portfolio across multiple advanced and difficult-to-treat tumor types, including #ovariancancer.
-
Regeneron
@Regeneron
We are honored to have supported the @AAOHNS Annual Meeting, an important opportunity for otolaryngologist-head and neck surgeons from around the world to convene and share the latest advancements in research and effective practices within the field. #otomtg23
-
Regeneron
@Regeneron
We are pleased to share that NEJM has published data from our Phase 3 clinical trial evaluating our treatment for people living with polymyalgia rheumatica (PMR). Learn more here: www.nejm.org/doi/full/10.1056/NEJMoa2303452
-
Regeneron
@Regeneron
Building on the success of our existing collaboration, weāre announcing the expansion of our research collaboration with @intelliatx to develop additional in-vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases.
-
Regeneron
@Regeneron
The U.S. FDA accepted for Priority Review the Biologics License Application for our investigational bispecific antibody in third-line relapsed/refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (#dlbcl).
-
Regeneron
@Regeneron
The U.S. FDA has accepted our application for Priority Review for our medicine for children ages 1 ā 11 with eosinophilic esophagitis (#eoe), a disease driven in part by type 2 inflammation that damages the esophagus. @SanofiUS
-
Regeneron
@Regeneron
Weāre excited to announce our acquisition of @DecibelTx, which strengthens our #genetherapy and hearing loss programs.
-
Regeneron
@Regeneron
Together with @msdebbieallen, and @PBA_savingsight, we created the Gr8 Eye Movement, a resource for those impacted by certain #retinaldiseases aiming to make eye health a top priority. Join the movement today: www.looktoyourfuture.com/gr8-eye-movement?cid=SM230901154903
-
Regeneron
@Regeneron
Together with @BARDA, we will be collaborating to develop a next-generation monoclonal antibody therapy for COVID-19 prevention #projectnextgen
-
Regeneron
@Regeneron
#breaking: The U.S. FDA has approved our treatment for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Learn more about the #fdaapproval and our ongoing commitment to those impacted by these #retinaldiseases: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
#breaking: The U.S. #fda has approved our treatment in CHAPLE disease, an ultra #raredisease characterized by damage to blood and lymph vessels along the upper digestive tract. Learn more about the approval.
-
Regeneron
@Regeneron
The European Medicines Agency accepted for review the marketing authorization application for our investigational bispecific antibody in third-line R/R #fl and R/R #dlbcl.
-
Regeneron
@Regeneron
Today, we shared positive two-year data from the pivotal clinical trial evaluating our treatment for people living with wet age-related macular degeneration. Learn more: investor.regeneron.com/news-releases/news-release-details⦠#retinaldiseases
-
Regeneron
@Regeneron
#breaking: We have announced our intention to acquire @DecibelTx, a clinical-stage biotech dedicated to discovering and developing transformative treatments for hearing and balance. Read important info: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
We are pleased to share that @JAMAOphth has published data from our Phase 2 clinical trial evaluating our treatment for people living with wet age-related macular degeneration. Learn more here: jamanetwork.com/journals/jamaophthalmology/fullarticle/28⦠#ophthalmology
-
Regeneron
@Regeneron
Today, we announced Q2 2023 results and are proud of our strong financial performance, pipeline progress and exceptional work delivering our medicines to patients in need.
-
Regeneron
@Regeneron
Join our Q2 2023 earnings webcast tomorrow morning at 8:30 AM ET: edge.media-server.com/mmc/p/hw3xhu4d
-
Regeneron
@Regeneron
In our ongoing pursuit of developing therapies for those impacted by certain #retinaldiseases like diabetic macular edema (DME), we presented 2-year data at @asrsdocs Annual Meeting this weekend. Learn more: investor.regeneron.com/news-releases/news-release-details⦠#asrs2023
-
Regeneron
@Regeneron
Announcing the 2022 'Agents of Change' AD Challenge grantāÆrecipients ā selected to help strengthen the self-esteem of those living with AD. Learn about the winning ideas from @EczemaOutreach, @SupportEczema,āÆ@eczemasociety, andāÆEpidermia at www.changead.com/initiatives/agents-of-change/index
-
Regeneron
@Regeneron
The rise of digital health technologies and digital biomarkers is ushering in a transformative era in clinical research. Dive deeper into the fascinating world and its potential to revolutionize drug development in our latest #regeneronperspectives #biomarkersgodigital
-
Regeneron
@Regeneron
We are announcing positive long-term data from our pivotal clinical trial program for our medicine in diabetic macular edema.Ā Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Sharing an update on the Biologics License Application (BLA) for our treatment in wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). Read more here: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron reposted
Society for Science
@Society4Science
The lottery for our High School Research Teachers Conference is now open! Apply to this all-expenses-paid, peer-led conference to help you empower your students through scientific research. @Regeneron #societyteach societyforscience.tfaforms.net/784
-
Regeneron
@Regeneron
Starting #pridemonth with a spotlight on our dynamic LGBTQ+ ERG! This talented team has driven our safe, supportive, inclusive culture, bolstering our LGBTQ+ colleaguesā experiences and growth. Discover more about our journey to a #betterworkplace in our DEI Annual Impact Report.
-
Regeneron
@Regeneron
At #asco23, weāre presenting positive Phase 1/2 data for our investigational bispecific antibody in relapsed/refractory #multiplemyeloma during an oral session on June 3. Learn more at the link below.
-
Regeneron
@Regeneron
Weāre presenting positive Phase 1 data for our investigational combination regimen with a LAG-3 inhibitor in advanced #melanoma as part of an oral session at #asco23. Learn more at the link below.
-
Regeneron
@Regeneron
Changing the paradigm in COPD requires us to re-think the science around this chronic, progressive disease. Learn more from Bola Akinlade in our new blog post, where he describes his own clinical experience and our science-first approach.
-
Regeneron
@Regeneron
This past week, our team presented at #asgct23 on our #genetic medicine work in CRISPR, antibody-based delivery, gene insertion and more. Weāre inspired by the research presented and the connections with fellow gene and cell therapy enthusiasts.
-
Regeneron
@Regeneron
We work every day to translate science into treatments that change lives, and are proud and grateful that a recent Supreme Court decision helps patients by protecting the scientific innovation emerging from Americaās thriving biopharma community. #regeneronperspectives
-
Regeneron
@Regeneron
Results from our Phase 3 COPD trial with @Sanofi are being presented for the first time at #ats2023 and published in @NEJM. COPD is a potentially life-threatening respiratory disease and is notoriously difficult to treat. Explore the results:
-
Regeneron
@Regeneron
Today we announced this yearās top #regeneronisef winners. Join us in congratulating our top 3 winners along with all our exceptional finalists on their inspiring innovations and outstanding research!
Post not available here, view on X
Regeneron
@Regeneron
Saathvik Kannan, of Colombia, Missouri, received one of two Regeneron Young Scientist Awards for using biocomputational methods to understand the causes of heightened infectivity in the disease mpox after it reemerged in 2022.
Regeneron
@Regeneron
Teepakorn Keawumdee, Pannathorn Siri, and Poon Trakultangmun, of Bangkok Thailand, received the second Regeneron Young Scientist Award for developing an incubation chamber that promotes the survival of the green lacewing insect, a natural predator of the mealybug, a harmful pest.
-
Regeneron
@Regeneron
Despite being the third leading cause of death worldwide, no new COPD treatment options have been approved in more than a decade. Together with @sanofi, we are committed to researching novel treatment approaches for people living with this burdensome respiratory disease.
-
Regeneron
@Regeneron
BREAKING: US Supreme Court issues unanimous opinion striking down Amgenās PCSK9 patent claims and defending scientific innovation, ending nearly 10-year dispute related to Regeneron-invented medicine.
-
Regeneron reposted
Society for Science
@Society4Science
Day one of #regeneronisef is in the bagš!
š RT if you're excited for the rest of the week!
@Regeneron -
Regeneron
@Regeneron
Today we hosted the #digitalbiomarker Summit USA, a collaborative event dedicated to bringing together thought leaders in the digital health technologies (DHT) space to discuss current work and future innovations. #biomarkersgodigital Learn more: digitalbiomarkersusa.panagorapharma.com
-
Regeneron
@Regeneron
Weāre presenting new research at #ats2023. Together with @SanofiUS we look forward to sharing our new clinical and real-world data in asthma and chronic obstructive pulmonary disease (COPD).
-
Regeneron
@Regeneron
New data in #eosinophilicesophagitis (EoE) appearing at #ddw2023. EoE is an inflammatory condition that can be difficult to manage, and we are committed to advancing scientific research to help change this trajectory. #ddw2023
-
Regeneron
@Regeneron
Linnea Texin, Senior Director, Corporate Responsibility, knows that when done well and authentically, corporate responsibility efforts can create a brighter, more sustainable future. Read about our progress & commitment to responsible business practices in her latest Perspective.
-
Regeneron
@Regeneron
Our year is off to a strong start with several regulatory approvals, important pipeline advancements and continued revenue growth. We are grateful to our colleagues around the world who lead with science and deliver life-changing medicines to those in need.
-
Regeneron
@Regeneron
Our Q1 2023 earnings webcast begins tomorrow morning at 8:30 AM ET.
Link: edge.media-server.com/mmc/p/zow3kngc -
Regeneron
@Regeneron
Weāre excited to head back to Chicago for #asco23 next month where weāll share new research on several difficult-to-treat cancers in our investigational portfolio like #melanoma and #multiplemyeloma, among others.
-
Regeneron
@Regeneron
With @Alnylam, today we announced positive interim Phase 1 data for our jointly developed investigational RNAi therapeutic for #alzheimersdisease.
-
Regeneron
@Regeneron
For 35 years, weāve harnessed the power of science to consistently bring innovative, life-changing medicines to patients, and 2022 was one of our most exciting yet. Check out our 2022 Year in Review, Responsibility Report and inaugural DEI Impact Report.
-
Regeneron
@Regeneron
With its abilityĀ to alter DNA sequences with precision, our team aims to use CRISPR biotechnology to disrupt disease causing genes or replace a missing factor in a given disease. Listen to @IAmBiotechās latest podcast to learn how our team uses this technology to advance science.
Biotechnology Innovation Organization
@IAmBiotech
#crispr has emerged as a powerful tool for altering #dna sequences with incredible precision. In the new #iambio episode, we explore the science behind it as well as its potential. Listen now: www.bio.org/podcast
@Regeneron @CRISPRTX @scribetx @BenjaminLOakes @JulianneBrun07
Regeneron
@Regeneron
Watch to learnĀ how weāreĀ deploying CRISPR technology to tackle difficult-to-treat genetic conditions. #spectacularscience.
-
Regeneron
@Regeneron
For over 20 years, we have been advancing retinal care for patients at risk of losing their vision. We look forward to presenting our data in wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) during #arvo2023.
-
Regeneron
@Regeneron
The impact of #atopicdermatitis can go beyond the skin, impairing quality of life for children living with the disease and their families. Learn about our published study exploring how young patients, caregivers and physicians perceive burden of disease. @eczemaresearch @Sanofi
Global Parents for Eczema Research
@eczemaresearch
New publication by @eczemaresearch & global research collaborators looking at alignment in perception of #eczema burden between pediatric patients, caregivers, and physicians. Children/youth & caregivers were more closely aligned than patients & physicians.link.springer.com/article/10.1007/s13555-022-00850-7
-
Regeneron
@Regeneron
Weāre honored to recognize our Data Technology & Engineering team as a @CIOonline 100 award winner. Their work leveraging cloud computing, artificial intelligence and machine learning is helping to save costs and reduce risks during the pre-manufacturing of our medicines.
CIO.com
@CIOonline
The CIO 100 & Hall of Fame Awards honor exceptional achievements in business technology, highlighting the contributions of organizations & tech leaders. These awards recognize innovation that drives business value & advances the tech industry as a whole.
www.linkedin.com/posts/foundryidg_cio-celebrates-innovati⦠-
Regeneron
@Regeneron
#breaking: The European Commission approved our medicine for first-line use in combination with chemotherapy in certain patients with advanced non-small cell lung cancer (#nsclc), marking our second indication in this cancer type in Europe.
-
Regeneron
@Regeneron
Weāre announcing a new collaboration that brings together Regeneronās industry-leading VelociSuite technologies with @SonomaBioās pioneering gene-modifying regulatory T cell therapy platform to potentially develop novel therapies for people with autoimmune diseases.
-
Regeneron reposted
Society for Science
@Society4Science
āI really hope someday Iāll find another young person who is interested and be that mentor for them."
@wxyzdetroit chats with #regeneronsts winner Neel Moudgal.
www.wxyz.com/news/positively-detroit/saline-teen-wins-nat⦠-
Regeneron
@Regeneron
Weāre sharing positive results from a Phase 3 trial of our medicine in adults with chronic obstructive pulmonary disease (COPD), a life-threatening respiratory disease that damages the lungs, leading to progressive decline in lung function. CC: @Sanofi
-
Regeneron
@Regeneron
Congratulations to our President and Chief Scientific Officer, George Yancopoulos, who recently received the Hellenic Heritage Achievement and National Public Service Award from @TheAHIinDC. His leadership inspires us daily to turn science into medicine to help people globally.
-
Regeneron
@Regeneron
#breaking: The U.S. FDA has approved our treatment for children aged 5 to 11 with #hofh, an ultra-rare genetic disorder that causes dangerously high levels of low-density lipoprotein cholesterol.
Read more here: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
The European Commission approved our medicine as the first of its kind to treat children as young as six months old with severe atopic dermatitis. CC: @Sanofi
-
Regeneron
@Regeneron
At #aad2023, weāre presenting late-breaking positive results from a Phase 3 trial in adults and adolescents with #atopicdermatitis of the hands and feet, a particularly difficult-to-treat form of the disease. @Sanofi
-
Regeneron
@Regeneron
New Orleans is home to 20+ historic districtsā21 to be exact. It is also home to this yearās #aad2023, where we are presenting #dermatology research from 20+ abstracts. Join us and check out the latest research.
-
Regeneron
@Regeneron
Tonight, we celebrated the top winners of the 2023 #regenetonsts! Congratulations to the top winners and to all of the finalists, whose outstanding research, innovation and creativity will shape the future of STEM.
@society4sciencePost not available here, view on X
Regeneron
@Regeneron
šCongrats to the 2023 #regeneronsts third place winner, Ellen Xu, for her project developing an algorithm using smartphone photos of patients to aid in the diagnosis of Kawasaki disease.
Regeneron
@Regeneron
We're so inspired by the incredible next generation of scientists. Read more and stay tuned as we continue to celebrate this year's #regeneronsts top winners and finalists!
investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron reposted
Society for Science
@Society4Science
Itās the @Regeneron Science Spectacular! š
Tonight the #regeneronsts finalists had a chance to hear from Regeneron scientists and ask them questions about making a career in STEM. š©āš¬šØšæāš¬ -
Regeneron
@Regeneron
Weāre hours away from announcing the winners of the 2023 #regeneronsts. Join us and @Society4Science live on YouTube tonight at 8 pm ET: www.youtube.com/watch?v=XgLb0gifFdQ
-
Regeneron
@Regeneron
Join us in celebrating the future of STEM as the #regeneronsts top 40 finalists present their innovative research during Finals Week, starting tomorrow! Learn more about their accomplishments and outstanding research: www.societyforscience.org/regeneron-sts/2023-finalists/
-
Regeneron
@Regeneron
This Myeloma ACTION Month, weāre excited to join @IMFmyeloma to highlight the inspiring stories of this resilient #multiplemyeloma community. Join us by sharing your #myelomastory.
International Myeloma Foundation
@IMFmyeloma
Today, we ask...
Have you ever dealt with relapse?
The IMF is grateful to @Regeneron for helping us share facts about this disease and amplifying your #myelomastory during Myeloma ACTION Month. -
Regeneron
@Regeneron
The U.S. FDA accepted for review our investigational medicine for chronic spontaneous urticaria (CSU). CSU is a chronic inflammatory skin disease that causes the sudden onset of hives on the skin and/or swelling deep under the skin. @SanofiUS
-
Regeneron
@Regeneron
Weāre excited to partner with @base11STEM on the STEM Superhero Challenge to spotlight the unseen heroes of STEM. Tell us about your personal STEM hero for a chance to win a cash prize and meet some of real-life STEM heroes at Regeneron. Enter by April 18: www.herox.com/STEMSuperhero
-
Regeneron
@Regeneron
The U.S. FDA has approved our medicine for the treatment of Polymyalgia Rheumatica.
@Sanofi -
Regeneron
@Regeneron
Weāre presenting our latest research in chronic, inflammatory diseases, including asthma, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria, at #aaaai23. Explore the data: @Sanofi
-
Regeneron
@Regeneron
The EMAās CHMP recommended approval of our medicine for use in combination with chemotherapy as first-line treatment in certain patients with advanced non-small cell lung cancer (#nsclc) in the European Union.
-
Regeneron
@Regeneron
The U.S. FDA has accepted for Priority Review the Biologics License Application (BLA) for our treatment in wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) ā two retinal conditions that can lead to vision loss. #ophthalmology
-
Regeneron
@Regeneron
.@Society4Science announced 52 teachers will receive awards through its STEM Research Grants program. We proudly sponsor this program to further hands-on science learning in middle and high school classrooms. Join us in congratulating this year's grantees: www.societyforscience.org/press-release/2023-stem-researcā¦
Society for Science
@Society4Science
Our STEM Research Grant provides support to teachers engaging their students in authentic scientific research by empowering them to give their students a plethora of hands-on research opportunities. Here are this year's awardees. www.societyforscience.org/blog/2023-stem-research-grants-ā¦
-
Regeneron
@Regeneron
Weāre announcing that the FDA accepted our application for Priority Review for an investigational treatment for CHAPLE, an ultra #raredisease characterized by damage to blood and lymph vessels along the upper digestive tract.
-
Regeneron
@Regeneron
āThe genome, our genome, is the how and why that defines who we are, where we come from and where we are going.ā Discover the possibilities unlocked with more genomics and less fear in our latest #regeneronperspective. @RegeneronDNA
-
Regeneron
@Regeneron
No attachment issues here. This Valentineās Day, weāre admiring antibodies that bind tightly to the targets they love, even withstanding the variants that come their way. Check out our work in Ebola, which is the cover feature in Cell Host & Microbe. @cellhostmicrobe
-
Regeneron
@Regeneron
"Find your north and donāt be afraid to try new things and experiences,ā is advice our own Ralph Hazlewood is sharing this #blackhistorymonth. Read more about his work and achievements in the field of ophthalmology in @ARVOinfo.
-
Regeneron
@Regeneron
Attending the Angiogenesis, Exudation, and Degeneration 2023 virtual meeting? Donāt miss the Feb. 11 sessions discussing Retinopathy of Prematurity (ROP). Learn more about the upcoming presentations. #retinaldisease
-
Regeneron
@Regeneron
#breaking: The U.S. #fda has approved our treatment for Retinopathy of Prematurity (ROP), a leading cause of childhood blindness worldwide. Read more about the FDA approval: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
We're excited to be recognized in the @SP_Global 2023 Sustainability Yearbook for the third year in a row. Our passion to create a better world extends beyond our labs as we continue in our commitment to support communities and protect and restore the planet.
-
Regeneron
@Regeneron
Our Q4 2022 earnings webcast begins this morning at 8:30 AM EST.
-
Regeneron
@Regeneron
The European Commission approved our medicine as the first & only targeted treatment for eligible adults and adolescents with eosinophilic esophagitis, a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly. CC: @Sanofi
-
Regeneron
@Regeneron
The CHMP recommended our medicine for approval in infants and young children as young as 6 months with severe atopic dermatitis.
CC: @Sanofi -
Regeneron
@Regeneron
Weāre excited to introduce the 2023 #regeneronsts finalists! These bright, young minds are channeling their curiosity and passion into research that explores solutions to some of the most complex, global issues. @Society4Science
-
Regeneron
@Regeneron
We are honored to be highlighted by the World Economic Forum Global Parity Alliance as part of the Diversity, Equity, and Inclusion (#dei) Lighthouse Programme 2023. Read more about this cross-industry group and our DEI strategy: www.weforum.org/reports/global-parity-alliance-diversity-ā¦
-
Regeneron
@Regeneron
As we modernize clinical trials, #patientcentricity is at the heart. Hear from Bari Kowal, SVP, Head of Development Operations & Portfolio Management, on key areas of innovation and their impact on the future of clinical development in @statnews:
-
Regeneron reposted
Renay Johnson
@RenayCJohnson
Congratulations to our Blazers, Regeneron Science Talent Search Scholars: Nathan Shan, Josh Wang, Celine Wu! ššš šš½
Regeneron
@Regeneron
With @Society4Science, we congratulate the 2023 #regeneronsts scholars, whose extraordinary research projects earned them a spot among an outstanding 300 peers.
Learn more about how these young scientists are using the power of STEM to contribute to our society. -
Regeneron
@Regeneron
With @Society4Science, we congratulate the 2023 #regeneronsts scholars, whose extraordinary research projects earned them a spot among an outstanding 300 peers.
Learn more about how these young scientists are using the power of STEM to contribute to our society. -
Regeneron
@Regeneron
Announcing a new PD-1 supply agreement with @senseibio to investigate potential combination therapy, which marks the 7th clinical supply agreement involving our PD-1 inhibitor in a year.
-
Regeneron
@Regeneron
#breaking: Japanās Ministry of Health, Labor and Welfare (MHLW) approved our #immunotherapy to treat advanced or recurrent #cervicalcancer in patients whose disease progressed on or after chemotherapy.
-
Regeneron
@Regeneron
The CHMP recommended the approval of our medicine for eligible adults and adolescents 12 years and older with eosinophilic esophagitis (EoE), a chronic, progressive disease of the esophagus driven by underlying type 2 inflammation. CC: @Sanofi
-
Regeneron
@Regeneron
Weāre proud that @USPTO selected Regeneron as a recipient of the COVID-19 Patents for Humanity Award. This award honors the innovation of our scientists who led the discovery and development of our COVID-19 treatment. Read more here: www.uspto.gov/blog/recognizing-life-saving-covid-19
-
Regeneron
@Regeneron
#breaking Our medicine was approved by the European Commission for adults with moderate-to-severe prurigo nodularis, a chronic skin disease associated with extreme itch. Read more: CC: @Sanofi investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
At #ash22, weāre presenting positive Phase 2 results from our investigational #bispecific antibody in relapsed/refractory #follicularlymphoma.
-
Regeneron
@Regeneron
During #ash22, weāre sharing positive Phase 1/2 data on our investigational #bispecific antibody in relapsed/refractory advanced #myeloma.
-
Regeneron
@Regeneron
Weāre proud to be recognized on the @SPGlobal #djsi World Index for the fourth year, and the #djsi North America Index for the third year. Each day, we focus on addressing issues that matter most to our people, society and business.
-
Regeneron
@Regeneron
Weāre presenting positive Phase 2 data from our investigational bispecific antibody in relapsed/refractory #dlbcl during an oral session at #ash22.
-
Regeneron
@Regeneron
We're excited to be at #ash22. Make sure to follow us on LinkedIn and Instagram to learn more.
-
Regeneron
@Regeneron
Weāre proud Regeneron has won the 2022 @PharmaScrip Community Partnership of the Year Award for our work with @Society4Science to sponsor the annual Science Talent Search. #scripawards
#regeneronsts
Together, weāre nurturing the next generation of scientists! -
Regeneron
@Regeneron
At #esmoimmuno22, weāre presenting research and insights from our diverse immuno-oncology pipeline, with data from seven abstracts across lung, ovarian, and cervical cancer. New insights span investigational candidates, combinations, and tumor types.
-
Regeneron
@Regeneron
The U.S. FDA accepted our application for Priority Review for our medicine being investigated in children aged 5 to 11 with #hofh, an ultra-rare condition that results in dangerously high levels of LDL-C, or bad cholesterol.
Learn more: investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
Congratulations to all those who competed in the 2022 #scifest National Final in Ireland! We canāt wait to see this yearās champion at #regeneronisef.
Department of Education and Youth
@Education_Ire
Congratulations to @SciFest4STEM winners Liam Waldron, Rachel Griffin & Luke O'Sullivan of @KillarneyCommu1: Group-Theoretic Approach to Pythagorasā Theorem. In May they will represent Ireland @ Regeneron International Science and Engineering Fair (ISEF) in Texas, USA.
@KerryETB -
Regeneron
@Regeneron
#breaking: The European Commission approved our #immunotherapy as a treatment option for recurrent or metastatic #cervicalcancer in Europe.
-
Regeneron
@Regeneron
Weāre announcing a new collaboration with @CytomXInc to develop next generation bispecific immunotherapeutics for the potential treatment of cancer. Read our press release to learn more.
-
Regeneron
@Regeneron
Congratulations to Kerry Reinertsen, Senior Vice President of Strategic Alliances, on being recognized among Westchesterās Top Women in Business of 2022 by @914INCBusiness.
Regeneron
@Regeneron
We applaud Kerryās tremendous contributions to Regeneron and her commitment to supporting rising women leaders. 914inc.com/westchester-women-business/
-
Regeneron
@Regeneron
Congratulations to Dr. Lori Morton, Vice President of Research, on being named one of the 2022 Fiercest Women in Life Sciences by @FiercePharma!
Beyond Loriās important work in the lab, she is committed to advancing women in science and STEM education. www.fiercepharma.com/special-reports/2022s-fiercest-women⦠-
Regeneron
@Regeneron
With in vivo CRISPR technology, the ability to cut and paste genetic code is at our fingertips as we work to tackle serious diseases right inside the body. #spectacularscience
-
Regeneron
@Regeneron
We ⤠scientists like @ravenscimaven who not only help advance our knowledge of the world but also give back to their communities through #stem education. In collaboration with @YonkersPartners and @CSHL, our partner Raven recently helped students with a biology experiment.
-
Regeneron
@Regeneron
The CHMP recommended the approval of our medicine in the EU for adults with moderate-to-severe prurigo nodularis, a chronic inflammatory skin disease characterized by intense itch and painful skin lesions. CC: @Sanofi
-
Regeneron reposted
Maya Ajmera
@MayaAjmera
Today is the final day to apply for #regeneronsts, so complete those applications by 8 p.m. tonight! My colleagues at @Society4Science and I can't wait to meet this next class of young innovators and learn all about their original research sciencetalentsearch.smapply.org
-
Regeneron
@Regeneron
#breaking: The U.S. FDA has approved our immunotherapy for use in combination with chemotherapy as first-line treatment in certain types of advanced #nsclc.
-
Regeneron
@Regeneron
During this yearās @RetinaSociety Meeting we presented positive data from our pivotal #clinicaltrial in wet age-related macular degeneration (#wetamd) and diabetic macular edema. #retinasociety2022
-
Regeneron
@Regeneron
Weāre excited to be sharing new research at #ash22 from 17 abstracts. Our data spans multiple investigational candidates from our hematology and hematologic oncology pipelines.
-
Regeneron
@Regeneron
Our Q3 2022 earnings webcast begins this morning at 8:30 AM EDT.
-
Regeneron
@Regeneron
Our DNA may hold the story of our history, but it is also writing our future. By building a database of around 2M sequenced exomes, the scientists of @RegeneronDNA use #ai and #machinelearning to mine the genetic superpowers found deep within a personās DNA. #spectacularscience
-
Regeneron
@Regeneron
Congratulations to the 2022 #prixgalien USA Award winners and our scientists who helped make this possible.
The Galien Foundation
@GalienFdn
And the winners are... #prixgalien galien.org/3TNl3FH
-
Regeneron
@Regeneron
Today, RGC's @MariaC_Su will present at #ashg22 on her latest research helping identify a potential therapeutic target for endometriosis. Learn more about RGCās latest genetic breakthroughs: www.regeneron.com/science/genetics-center
Regeneron Genetics Center
@RegeneronDNA
Find out what has @MariaC_Su excited for her #ashg22 plenary session. Catch it live tonight at 5:30 PM PT.
-
Regeneron
@Regeneron
Congratulations to Chris Fenimore, our SVP, Head of Accounting and Controller, who received a @WestfairOnline 2022 C-Suite Award.
Chrisās strategic mindset & dedication to collaboration have helped shape Regeneron since he joined in 2003! westfaironline.com/csuite2022/ -
Regeneron
@Regeneron
We are proud to announce our #ebola medicine, the first FDA-approved recombinant monoclonal antibody for this devastating disease, was recognized as the #prixgalien "Best Biotechnology Product of 2022" by the @GalienFdn.
-
Regeneron
@Regeneron
Our @RegeneronDNA colleagues continue to advance our scientific understanding of the drivers behind genetic disease. Follow along with their content throughout #ashg22 to get a closer look at their upcoming presentations and coffee chats!
Regeneron Genetics Center
@RegeneronDNA
In February of 2020, we sequenced our 1,000,000th exome, creating a robust and diverse database to aid in genetic discovery and serve as a resource for the scientific community. Suganthi Balasubramanian shares how we achieved this milestone in her #ashg22 presentation.
-
Regeneron
@Regeneron
Weāre proud that @ScienceMagazine has again named us a Top Biopharma Employer. Itās a testament to our efforts to turn #science into life-changing medicines & put our employees, patients, and communities at the center of every decision we make. www.science.org/content/article/2022-s-top-employers-provā¦
-
Regeneron
@Regeneron
Our President and CEO, Len Schleifer, joined in on #regenerond4dg to help his colleagues nurture a love of STEM among local school children. āThe 1000 assembled āSTEM-TASTICā Project Kits help teach and reinforce concepts around engineering and the design process.
-
Regeneron reposted
Sheba Medical Center
@sheba_medical
#shebamedical signed an agreement with @Regeneron focusing on accelerating #oncology research and delivering novel therapeutics. Regeneron will also sponsor Sheba's ARC innovation center, where a "personalized medicine" development hub is creating new solutions forĀ #patientĀ care.
-
Regeneron
@Regeneron
Thatās a wrap on our first day of #regenerond4dg! Check out some of our amazing colleagues who volunteered their time today.
-
Regeneron
@Regeneron
Today marks the start of our annual Day for Doing Good, our company-wide global days of service. Stay tuned to hear how our teams are Doing Well by Doing Good through volunteer activities this week.
-
Regeneron
@Regeneron
Today we announced the FDA has granted Regeneron pediatric exclusivity for our medicine in ophthalmology. Learn more about this announcement here investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Our recent preclinical discovery published in @CellReports used #crispr screens to illuminate role of nuclear envelope integrity as a possible origin of #alzheimers and other neurodegenerative diseases.
Post not available here, view on X
Regeneron
@Regeneron
In #alzheimers and other neurodegenerative diseases, ātanglesā of the protein tau are found in patientsā brains. Our discovery identifies genes that modify tau tangles by increasing or reducing their formation. #cellreports
Regeneron
@Regeneron
These genes are also involved in the maintenance and repair of the nuclear envelope: the barrier that surrounds the nucleus and protects the genetic material from the rest of the cell. This timelapse video shows images of live cells revealing nuclear leakage. #cellreports
-
Regeneron
@Regeneron
The countdown is on for our 6th annual, global Day for Doing Good ā kicking off on October 21. Our colleagues have historically outdone themselves in their support and service - and we have no doubt this #regenerond4dg will be the best yet.
-
Regeneron
@Regeneron
Our DNA makes us unique and is where our superpowers may be hidden. By diving into a database of around 2M sequenced exomes - the functional parts of DNA - @RegeneronDNAās uncovering the hidden heroes that may spark the future of genetics-based medicine. #spectacularscience
-
Regeneron
@Regeneron
We are pleased to announce that Gina Thomas, our Executive Director of Talent Acquisition, has been named one of @CrainsNewYork's 2022 Notable HR Leaders.
Under Gina's leadership, we've transformed our recruitment process for the better! www.crainsnewyork.com/awards/notable-hr-leaders-2022 -
Regeneron
@Regeneron
Starting this month, any high school teacher can apply for the @STEMResConsult ASRT program. We are proud to support in improving the skills of science educators and creating hands-on research opportunities for students.
-
Regeneron
@Regeneron
#breaking: Today the @EMA_Newsās CHMP granted a positive opinion recommending approval of our #immunotherapy in recurrent or metastatic #cervicalcancer in Europe. #gyncsm
-
Regeneron
@Regeneron
Biology and technology, a match weāre swiping ā”ļø on. Discover how this union has fueled the creation of our cutting-edge technological toolkit. #spectacularscience
-
Regeneron
@Regeneron
The U.S. FDA has accepted our sBLA for priority review in retinopathy of prematurity (ROP), an eye disease that can cause vision loss and blindness in premature babies.
-
Regeneron
@Regeneron
Weāre presenting late-breaking Phase 3 data with @Sanofi for our medicine in children aged 1 to 11 years with eosinophilic esophagitis, a chronic disease that can make it difficult to swallow food. Learn more at #uegweek:
-
Regeneron
@Regeneron
š§Its time to pause for mental healthāøļø
In honor of #worldmentalhealthday our employee resource group (ERG), Resilience is Essential (RisE), encourages brief pauses for breathing or movement. Join along below for some refreshing, desk-friendly stretches. -
Regeneron
@Regeneron
Check out our new data in patients with eosinophilic esophagitis (EoE), a chronic disease with underlying type 2 inflammation that can affect a personās ability to swallow food, at #uegweek and #acg2022: gi.org @Sanofi
-
Regeneron
@Regeneron
Uncovering rare genetic mutations and associated disease risk can only be achieved through teamwork. In our latest #regeneronperspectives, discover the collective effort alongside our colleagues at @RegeneronDNA that led to a breakthrough in liver disease.
-
Regeneron
@Regeneron
We welcome Dr. Craig B. Thompson to our Board of Directors. Dr. Thompson brings a unique combination of business and scientific leadership, with a distinguished career in immuno-oncology, translational research, and precision medicine.
-
Regeneron
@Regeneron
#breaking: Our team is presenting positive data in #wamd and #dme during the 2022 @aao_ophth (#aao22) meeting. #ophthalmology investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
#breaking: The FDA approved our medicine as the first treatment for adults with #prurigonodularis, a chronic disease with underlying type 2 inflammation that can cause extreme itching and the formation of nodules on the skin. Read more: investor.regeneron.com/news-releases/news-release-detailsā¦. @Sanofi
Regeneron
@Regeneron
Our President and Chief Scientific Officer, George Yancopoulos, reflects on the significance of this milestone. Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦.
@Sanofi -
Regeneron
@Regeneron
Congratulations to the DNA Diversity Challenge 1st place winners, Areahna O'Rea and Chanda Lowrance, who submitted proposals to increase Black American participation in genomics research. Their ideas will help us grow representation in this cutting-edge research!
HeroX
@Iamherox
Congratulations to the winners of the DNA Diversity Challenge, sponsored by @Regeneron and @base11STEM! Check out who was selected in the Influencer and Collaboration categories to share the $14,500 prize: www.herox.com/DNAdiversity/update/5008?hss_channel=tw-170ā¦
-
Regeneron
@Regeneron
At our core, we believe the best and brightest ideas come from all backgrounds. Our values of building a better workplace, better science, and a better world guide our culture. Visit our DEI page to learn more: www.regeneron.com/responsibility/diversity-inclusion
-
Regeneron
@Regeneron
Congratulations to Smita Pillai on being named one of @AABDCās 2022 Outstanding 50 Asian Americans in Business!
Smita has helped continue to build a culture of belonging where we can all thrive while pursuing Regeneron's mission. www.aabdc.com/post/smita-pillai -
Regeneron
@Regeneron
Today at #klickidx, our President & CSO, George Yancopoulos, spoke with @roncohenshair on āThe Next Frontier of Scienceā in #biopharma. The future is clear for us - continue to push the bounds of science to make life changing medicines.
-
Regeneron
@Regeneron
Our environmental targets reflect our ambitions to reduce GHG emissions, increase our use of renewable energy, minimize waste and enhance water stewardship to protect and restore the planet. To revisit our 2025 environmental targets, click the images below. #climateweeknyc šĀ š
-
Regeneron
@Regeneron
#breaking: Today, with our partner @intelliatx, we announced interim results from the #cardiomyopathy arm of an ongoing phase 1 study of our investigational #crispr therapy for the treatment of transthyretin (#attr) amyloidosis. Read the press release to learn more.
-
Regeneron
@Regeneron
.@TheLancet has published Phase 3 data for our medicine in children aged 6 months to 5 years with uncontrolled moderate-to-severe #atopicdermatitis. Learn more: investor.regeneron.com/news-releases/news-release-details⦠@Sanofi
-
Regeneron
@Regeneron
#breaking: Together with @Alnylam we announced promising phase 1 results for our investigational therapy for #nash. Learn more at the link below.
-
Regeneron
@Regeneron
#breaking: We announced positive Phase 2 investigational data in neoadjuvant #cscc, presented today at #esmo22 and published in @NEJM. Learn more at the link below.
-
Regeneron
@Regeneron
At #esmo22, we presented positive Phase 1 data for an investigational combination regimen with a LAG-3 inhibitor in advanced #melanoma. Learn more at the link below.
-
Regeneron
@Regeneron
At #esmo2022, we are sharing first-in-human data in two novel investigational bispecific antibodies in advanced solid tumors.
-
Regeneron
@Regeneron
At #eadv2022, weāre presenting late-breaking results from a second positive Phase 3 trial in adults with #prurigonodularis ā a debilitating disease characterized by unrelenting itch. Read the news: investor.regeneron.com/news-releases/news-release-details⦠@Sanofi
-
Regeneron
@Regeneron
#breaking: We are announcing positive data from our pivotal #clinicaltrials in patients with diabetic macular edema and #wetamd - two leading causes of vision loss in the U.S.
-
Regeneron
@Regeneron
Cancer treatment has come a long way thanks to new technology and research, but we know there is still more to do. Our own Dr. Israel Lowy shares thoughts on the future of #cancercare and oncology research. #esmo22
-
Regeneron
@Regeneron
Weāre presenting long-term Phase 3 data with @Sanofi for our medicine in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma at #erscongress. Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Weāre presenting long-term Phase 3 data with @Sanofi for our medicine in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma at #erscongress. Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
We are sharing new research at #esmo22 from 16 abstracts covering our expanding clinical portfolio in #oncology. New insights span multiple investigational candidates, combinations, and tumor types.
-
Regeneron
@Regeneron
Explore our latest research in respiratory diseases driven by type 2 inflammation at #erscongress, including late-breaking, long-term results in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma: www.ersnet.org/congress-and-events/congress/ @Sanofi
-
Regeneron
@Regeneron
Question everything ā itās part of our DNA and what drives us to harmonize #biology and #technology. Find out how our scientists are working to solve healthcareās greatest mysteries by asking āwhatās next?'
-
Regeneron
@Regeneron
Congratulations to @thermofisher for being named as the 2023 middle school STEM competition title sponsor - a collaboration that will provide opportunities for thousands of future scientists! Learn more from @Society4Science: www.societyforscience.org/blog/thermo-fisher-scientific-tā¦
Society for Science
@Society4Science
We're thrilled to welcome @thermofisher as the title sponsor for our middle school competition! www.societyforscience.org/blog/thermo-fisher-scientific-tā¦
-
Regeneron
@Regeneron
Congratulations to @bethfholly, who was named one of @CrainsNewYorkās 2022 Notable Health Care Leaders! Bethās leadership has advanced our compliance programs and elevated diversity and inclusion initiatives within Regeneron and in her community. www.crainsnewyork.com/awards/beth-holly-notable-healthcarā¦
-
Regeneron
@Regeneron
Whatās next? A simpleāÆquestion that is part of our teamās DNA. To answer this, weāve harmonized #biology and #technology to make fully human antibodies that tackleāÆserious diseases. And thatās only the beginning. #spectacularscience
This media couldn't be displayed. See it on the original post. -
Regeneron reposted
Society for Science
@Society4Science
We're excited to announce the 2022-23 #societyadvocates! These mentors are uplifting the next generation of scientists. www.societyforscience.org/blog/society-for-science-awardsā¦
-
Regeneron
@Regeneron
As a part of our commitment to building sustainable communities, our IOPS Raheen EHS, Facilities & Engineering teams set out to restore the Roche Castle, built around 1830, and its surrounding land in Limerick, Ireland. Check out the progress weāve made!
Regeneron
@Regeneron
To celebrate #heritageweek2022Ā in Ireland we shared ourĀ excitingĀ progress with local historians and environmentalists. Thank you to those whoĀ joined us in honoring the rich history of the local community of Limerick.
Regeneron
@Regeneron
This restoration work is part of our BeaCON program, a biodiversity and conservation initiative. Our year-round programs engage employees, promote sustainable preservation and conservation, and identify invasive and non-invasive species. Learn more:Ā investor.regeneron.com/2021RR
-
Regeneron
@Regeneron
Imagine itās 1988, youāre a young scientist who knows the key to human health is in our genes, but the technology to turn that knowledge into medicine doesnāt exist yet. So, you build it. Thatās our origin story. See where weāve been and whatās next for our #spectacularscience.
-
Regeneron
@Regeneron
Our Q2 2022 earnings webcast begins this morning at 8:30 AM EDT. edge.media-server.com/mmc/p/gd3eg2fo
-
Regeneron
@Regeneron
Regeneron shares initial data from ongoing Phase 1/2 trial of costimulatory bispecific antibody in combination with PD-1 inhibitor in advanced metastatic castration-resistant prostate cancer. Read more here: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
This breakthrough discovery by @RegeneronDNA has allowed us to initiate new preclinical research programs, furthering our work with collaborators such as @Alnylam as we search to find new potential therapies for previously untreatable conditions like #nash.
Regeneron Genetics Center
@RegeneronDNA
Our latest research identified mutations in the CIDEB gene that are highly protective against nonalcoholic forms of liver disease. We're using this discovery to bring potentially promising new therapies to the clinic to help people with NASH. #rgcresearch
-
Regeneron
@Regeneron
How do you nurture the next scientific innovators? Kickstart their careers with internships! Hear from our talented summer interns from across the globe in our latest #regeneronperspectives! #regeneronintern šš„½š www.regeneron.com/about/perspectives/defining-internship-ā¦
-
Regeneron
@Regeneron
#breaking In the largest sequencing study to date to better understand how genetic mutations can cause or prevent liver disease, @RegeneronDNA uncovered rare genetic mutations in the CIDEB gene associated with protection from nonalcoholic liver disease and nonalcoholic cirrhosis.
-
Regeneron
@Regeneron
Congratulations to the winners of the 10th annual Regeneron Prize for Creative #innovation. They pushed the boundaries of #science with their research. newsroom.regeneron.com/news-releases/news-release-detailsā¦
Regeneron
@Regeneron
Dr. @REmenecker of @WUSTL School of Medicine received the Regeneron Prize for Creative Innovation by a Postdoctoral Fellow. newsroom.regeneron.com/news-releases/news-release-detailsā¦
Regeneron
@Regeneron
.@SaiChaluvadi of @Penn received the Regeneron Prize for Creative Innovation by a Graduate Student. newsroom.regeneron.com/news-releases/news-release-detailsā¦
Regeneron
@Regeneron
.@EsbinMeagan of @UCBerkeley received an honorable mention. newsroom.regeneron.com/news-releases/news-release-detailsā¦
Regeneron
@Regeneron
Visit our website to learn more about our #stem education programs: www.regeneron.com/responsibility/sustainable-communities
-
Regeneron
@Regeneron
Congrats to our President and CEO, Len Schleifer, who was recognized as one of @914INCBusinessā CEOs & Business Leaders of the Year for his exceptional leadership and commitment to solving the worldās biggest challenges.
-
Regeneron
@Regeneron
Our philosophy, Doing Well by Doing Good, holds true in every aspect of our business and carries through to the teams we engage with. To us, there's importance in doing well by our patients, shareholders and beyond in order to foster a culture of trust and excellence.
-
Regeneron
@Regeneron
Do you have ideas on how to increase diverse participation in genomic research? We want to hear them! Submit your ideas through our DNA Diversity Challenge in collaboration with @base11STEM by July 27th. #b11nextfrontier #stem
-
Regeneron
@Regeneron
#breaking: Weāre reporting the first positive Phase 3 trial in children 1 to 11 years of age with eosinophilic esophagitis, a painful disease with underlying type 2 inflammation that can affect a personās ability to swallow food. Learn more: investor.regeneron.com/news-releases/news-release-details⦠CC: @Sanofi
-
Regeneron
@Regeneron
Weāre at #eczemaexpo2022! Our Senior Director of Patient Advocacy, Ilana Tabak, is speaking at a panel with @nationaleczema on the value of the patient and caregiver perspective in healthcare. eczemaexpo2022.us2.pathable.com/meetings/3FZHAy5Eb8rm4hjHg
-
Regeneron
@Regeneron
For the sixth consecutive year, we have been named to @pointsoflight's #thecivic50 list of most community-minded companies in the U.S. #responsibleregeneron Learn more: www.pointsoflight.org/the-civic-50-honorees/
-
Regeneron
@Regeneron
Together with @SanofiUS, weāre proud to support organizations that share our commitment to advocacy and research for advanced non-melanoma skin cancers. Read more about their work below. š 1/4
Post not available here, view on X
Regeneron
@Regeneron
The second most common #skincancer is called #cutaneoussquamouscellcarcinoma (CSCC). It can be easily treatable if caught early but can be serious if it advances.
Visit @SkinCancerOrg to learn more about CSCC. www.skincancer.org/skin-cancer-information/squamous-cell-⦠CC: @SanofiUS. 3/4
Regeneron
@Regeneron
Looking for more #nonmelanoma #skincancer resources and advocacy groups? Visit @SanofiUS. 4/4
-
Regeneron
@Regeneron
We have completed the acquisition of Sanofiās stake in our Libtayo (cemiplimab) collaboration.
-
Regeneron
@Regeneron
Our colleaguesā volunteerism and commitment to making a positive impact is as inspiring as their talent. Hear from Potoula Stavropoulos, our Senior Director of Social Impact, about our Using Data for Good program with the Taproot Foundation that applies skills to help nonprofits.
-
Regeneron
@Regeneron
In recognition of the 10th anniversary of Cancer Immunotherapy Month, Andres Sirulnik, our SVP, Translational and Clinical Sciences, Hematology, highlights Regeneronās approach to cancer research.
-
Regeneron
@Regeneron
The U.S. FDA has accepted our supplemental Biologics License Application for a new investigational dosing regimen for our medicine in adults with #diabeticretinopathy, a retinal disease that can develop in anyone who has type 1 or type 2 #diabetes.
-
Regeneron
@Regeneron
Together with @intelliatx, we're announcing more positive interim data around an investigational treatment for transthyretin (ATTR) amyloidosis, a condition where abnormal protein deposits build up in the body. Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron reposted
Getting Smart
@Getting_Smart
Regeneron Science Talent Search on Science Projects That Matter www.gettingsmart.com/podcast/regeneron-science-talent-seaā¦
-
Regeneron
@Regeneron
Congrats to @LinneaTexin for being named to the @WestchesterBiz 2022 Rising Stars #fortyunder40. Linnea embodies our values by establishing and leading our corporate responsibility priorities globally and in our local Westchester community. #regeneron
-
Regeneron
@Regeneron
This June marks the 10th anniversary of Cancer Immunotherapy Month. Learn more about our approach to innovation in investigating immunotherapies ā what we call Immunotherapy 2.0. #cim22
-
Regeneron reposted
Regeneron Genetics Center
@RegeneronDNA
#pride is in the DNA of our workplace and @Regeneron's as we foster a culture of authenticity, equality and allyship. Thatās why not just this Pride month, but every day is a chance for us to celebrate our LGBTQ+ colleagues. We stand for justice with joy. š³ļøāš
-
Regeneron
@Regeneron
After a year of incredible growth, change, and forward-thinking innovations, weāre thrilled to be named as one of @Fortuneās Best Workplaces in New York 2022!
-
Regeneron reposted
NowThis Impact
@nowthisimpact
Despite fleeing their homes amid Putinās war, these high schoolers proved Ukraineās strength by earning international science fair awards ā hereās what theyāve been working onš¬
This media couldn't be displayed. See it on the original post. -
Regeneron
@Regeneron
#breaking: The FDA approved our medicine for children aged 6 months to 5 years with uncontrolled moderate-to-severe #atopicdermatitis. Read more: investor.regeneron.com/news-releases/news-release-details⦠CC: @Sanofi
-
Regeneron
@Regeneron
We are continuing our research with bispecific antibodies. Learn more about our ongoing clinical trial evaluating our investigational bispecific antibody in patients with metastatic castration resistant prostate cancer: meetings.asco.org/abstracts-presentations/search?q=*
-
Regeneron
@Regeneron
Weāre presenting information at #asco22 on the design of our clinical trial of investigational agents in patients with MET-overexpressing #nsclc, a patient population in-need of therapeutic options. Read more about the trial in progress here: meetings.asco.org/abstracts-presentations/search?q=*
-
Regeneron
@Regeneron
From restoring a castle in Ireland to preserving habitats in our communities, our teams use their time, talent and influence to create a better world. Discover more about our goals to protect and restore our planet. #worldenvironmentday #regeneroniops
-
Regeneron
@Regeneron
Congratulations to @MatthewIto, Associate Director of Medical Affairs, on receiving the Master of NLA Designation from @nationallipid!
-
Regeneron
@Regeneron
#multiplemyeloma predominantly affects older individuals, so understanding comorbidities to optimally manage the disease is critical. This #asco22 we are sharing real-world findings on the prevalence of ocular comorbidities in patients with MM. Learn more: meetings.asco.org/abstracts-presentations/search?q=*
-
Regeneron reposted
Society for Science
@Society4Science
š£ļø SPREAD THE WORD! š£ļø
Applications for the 2023 @Regeneron Science Talent Search are now open! If you're an incoming high school senior, apply by November 9 at 8pm ET for a chance to win the top prize of $250,000. #regeneronsts sciencetalentsearch.smapply.org -
Regeneron
@Regeneron
Despite increasing advancements in #multiplemyeloma research, available therapeutic options can lead to high healthcare costs and poor outcomes for patients. Weāre presenting data on real-world outcomes in RRMM at #asco22. Learn more: meetings.asco.org/abstracts-presentations/search?q=*
-
Regeneron reposted
Sheila Porter
@SheilaEPorter
So many happy faces at SciFest @IDTCD today! What a wonderful way to close the school year. It was so good to be back meeting these exceptional young people face to face. @mariedevitt @SchoolofEdTCD @Daraghfallon @LindaDoyle @Society4Science @Regeneron @Intel_IRL
-
Regeneron
@Regeneron
Congratulations to Huda Zoghbi, who sits on our Board, for being awarded the 2022 Kalvi Prize in Neuroscience for her genetic discoveries! The Kalvi Prize celebrates groundbreaking scientists who revolutionize the worldās understanding of science.
The Kavli Prize
@KavliPrize
JUST ANNOUNCED
#kavliprize2022 #neuroscience honors Jean-Louis Mandel, Harry Orr, Christopher Walsh and Huda Zoghbi for pioneering the discovery of genes underlying a range of serious brain disorders and elucidating the pathways by which these genes work.
www.kavliprize.org/prizes/neuroscience/2022 -
Regeneron
@Regeneron
Meet the 2021 āAgents of Changeā AD Challenge grant recipients and see how theyāre helping to promote change for families with atopic dermatitis (AD).
Sanofi
@sanofi
Worldwide, families are impacted by atopic dermatitis. With @Regeneron, weāre announcing the 2021 āAgents of Changeā AD grant recipients @eczemaresearch, @GA2P2, @AlerjiDernegi, COPAC, Israeli Assoc. for AD & their ideas to help these families. Learn more: www.changead.com/initiatives/agents-of-change/
-
Regeneron
@Regeneron
From the start, corporate responsibility has informed every part of our business ā including our environmental practices. Read more about our systems that ensure:
ā Resiliency
ā Continuous Improvement
ā GHG Emissions Reductions -
Regeneron
@Regeneron
Research is integral to scientific progress, which is why weāre joining the #cardiometabolicdiseases community at the @nationallipid Congress.
Learn about our efforts to advance research for those with high unmet needs, like #hofh: www.regeneron.com/about/perspectives/hofh-treatment-discoā¦.
#nlasessions -
Regeneron
@Regeneron
Today we announced our further commitment to oncology by purchasing Sanofiās stake in our Libtayo collaboration. We now have exclusive development, commercialization and manufacturing rights to the PD-1 antibody that was originally invented using our VelocImmune technology.
-
Regeneron
@Regeneron
Weāre excited to announce the completion of our acquisition of @CheckmatePharma, which deepens and expands our efforts in #immunooncology. investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
The U.S. FDA has accepted our medicine for Priority Review in adults with #prurigonodularis, a chronic inflammatory skin disease that causes extreme itch and skin lesions (nodules). @Sanofi
-
Regeneron
@Regeneron
Our leaders embody the core Regeneron values that enable us to develop life-changing medicines and have a positive impact on our communities. Hear directly from them on how our culture helps us strive to make a difference in peopleās lives.
-
Regeneron
@Regeneron
Together with @Sanofi, weāre presenting data for our investigational medicine in patients with eosinophilic esophagitis (EoE) at #ddw2022, showcasing our efforts to address a major underlying cause of #eoe: type 2 inflammation.
-
Regeneron
@Regeneron
At #eas2022, we presented Phase 3 results from a pivotal trial in pediatric patients with homozygous familial hypercholesterolemia (#hofh). Read more here.
-
Regeneron
@Regeneron
#breaking: The FDA approved our medicine as the first for patients aged 12 years and older with #eoe, a chronic type 2 inflammatory condition that damages the esophagus. Read more: newsroom.regeneron.com/news-releases/news-release-details⦠CC: @Sanofi
Regeneron
@Regeneron
Our medicine is now the first and only FDA-approved treatment for patients aged 12 years and older with eosinophilic esophagitis (#eoe), a type 2 inflammatory condition that damages the esophagus. Learn about what this means for patients: newsroom.regeneron.com/news-releases/news-release-details⦠@Sanofi
-
Regeneron
@Regeneron
We celebrate the researchers, patients and participants who push the frontiers of science and blaze trails in trialsāleading to potential new discoveries, new medicines, and new hope. #clinicaltrialsday #ctd2022
-
Regeneron
@Regeneron
We challenged #regeneronisef students to participate in Create-a-thon; our workshop dedicated to explaining high-impact science through social media content. Take a look at one team's #stem4all video.
-
Regeneron
@Regeneron
Whether you had major FOMO last week, or you just want to relive the amazing science at this year's #regeneronisef, we can't wait for @NatGeoTV's new documentary all about our global #sciencefair.
National Geographic TV
@NatGeoTV
And finally, producers of the Emmy-winning documentary #sciencefair are back with even more experiments, tense competition, and a cast of students you'll fall in love with all over again, in Science Fair: The Series! š¤©
-
Regeneron
@Regeneron
#healthyvisionmonth is an important time to discuss the connection between diabetes and healthy vision. Through partnerships with @PBA_savingsight and the @AmDiabetesAssn, we're working to elevate the understanding of the impact diabetes related eye diseases can have on the eye.
-
Regeneron
@Regeneron
Join us in congratulating our top #regeneronisef winners! šš§āš¬ Weāre inspired by the top three students and the next generation of scientific leaders.
-
Regeneron
@Regeneron
We are reminded that brilliance can come from anywhere as we are joined by nearly 1,800 students from 60+ countries here at #regeneronisef. Now let's recognize the hard work and innovative thinking of these STEM leaders! @Society4Science
-
Regeneron
@Regeneron
Our own President and Chief Scientific Officer George Yancopoulos is in his (periodic) element among this year's group of bright #regeneronisef scientists.
Society for Science
@Society4Science
A special fireside chat with @Regeneron President and Chief Scientific Officer George Yancopoulos. #regeneronisef
-
Regeneron reposted
Dr. Raven the Science Maven
@ravenscimaven
#ad Hey Everyone! Did you know #regeneronisef Opening Ceremony is tonight? This is the world's largest STEM fair which features 1,750 impressive students representing 63 countries from Ukraine to Ghana to Peru. Join me and tune in at 7 PM ET: www.youtube.com/watch?v=RaU0YcIoJOE @Regeneron
Society for Science
@Society4Science
#regeneronisef programming starts next week! Tune in to the Opening Ceremony on May 9 at 7pm ET. youtu.be/RaU0YcIoJOE
-
Regeneron
@Regeneron
To support our teamās overall wellbeing, we cultivate a culture that promotes mental health for all our colleagues and their families. #mentalhealthawarenessmonth
-
Regeneron
@Regeneron
We are honored to receive @YWCAWhitePlains Community Partner Award at their "In The Company of Women" event for our commitment to supporting and elevating women. We hope youāll join us on May 6.Ā ywca.onlinegalas.com
-
Regeneron
@Regeneron
On Sunday, hundreds participated in the Regeneron Great Limerick Run, one of Irelandās largest mass participation events. Congratulations to all this yearās participants and finishers who worked together towards a common goal of health and community. #rglr2022 @RGreatLimRun
This media couldn't be displayed. See it on the original post. -
Regeneron reposted
Regeneron Genetics Center
@RegeneronDNA
We are honored to be named among @FastCompany's #fcworldchangingideas for uncovering a protective mutation in the gene known as GPR75, pinpointing a new therapeutic target for obesity. We thank our colleagues and collaborators for their research that made this finding possible.
-
Regeneron
@Regeneron
Our Q1 2022 earnings webcast begins this morning at 8:30 AM EDT.
-
Regeneron
@Regeneron
Developing treatments for hematological diseases is no easy feat. L. Andres Sirulnik, our SVP, Clinical Development, #hematology, shares how his team is poised to help make a difference for patients in need. Read the @Pharma_Intell article here: pages.pharmaintelligence.informa.com/regeneron-hematologyā¦
-
Regeneron
@Regeneron
Our Volunteer of the Year Award recognizes our colleagues who lead by example by using their time and talents to meaningfully impact their communities. This year, weāre thrilled to honor 8 outstanding Regeneron employees!
-
Regeneron
@Regeneron
On this #worlddayforsafetyandhealthatwork, weāre proud that 100% of our IOPS employees participated in our programs to improve safety, efficiencies and quality. Learn more: investor.regeneron.com/2021RR
-
Regeneron
@Regeneron
To celebrate the power of volunteering as a collective force for good, last week our employees engaged in several activities for #nationalvolunteerweek. Thank you for motivating young mathematicians and supporting Ukrainian relief efforts.
-
Regeneron reposted
Regeneron Genetics Center
@RegeneronDNA
Today is a milestone for our RGCers, itās #dnaday! Read through some of our favorite DNA facts that are sure to shock, entertain and inform.
-
Regeneron
@Regeneron
We're halfway toward our 2025 goals and while there is much work to be done, we're inspired by our progress and what's ahead. Hear from Christina Chan on how we're striving for impact through corporate responsibility and what has surprised her since she joined our company.
-
Regeneron
@Regeneron
Check out our 2021 Year in Review website ā a spotlight on how we are constantly working to improve the drug discovery and development process by applying our homegrown technologies, deep understanding of science, and relentless spirit.
-
Regeneron
@Regeneron
By reducing emissions, composting waste, and improving water efficiencies, we strive to make a more sustainable world. This #earthday, weāre proud to #investinourplanet and share the progress we made in 2021.Ā #responsibleregeneron
-
Regeneron
@Regeneron
Each year, we build on our long-standing commitment to responsible business practices and transparency, and weāre pleased to share our 2021 progress.
Announcing our:
2021 Responsibility Report: investor.regeneron.com/2021RR
2021 Year in Review: yearinreview.regeneron.com -
Regeneron
@Regeneron
Up for a challenge? Tell us your ideas on how to increase diverse participation in genomics research through our DNA Diversity Challenge in collab with @base11STEM! Learn more here: www.herox.com/DNAdiversity/teams #b11nextfrontier #stem
-
Regeneron
@Regeneron
Todayās news: Regeneron to acquire @CheckmatePharma and its investigational immune activator for potential use in multiple tumor types. Read more here: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron reposted
TODAY
@TODAYshow
āI wanted to make a program that could help other families from having to deal with this type of loss.ā on.today.com/3uKWtLO
-
Regeneron
@Regeneron
The #fda has extended the BLA review period by three months for our investigational COVID-19 antibody cocktail for the treatment of non-hospitalized patients and as prophylaxis in certain individuals.
-
Regeneron
@Regeneron
What is an automated biobank? We store millions of samples of RNA, DNA and protein reagents in a network of customized robotic cold storage systems called biobanks. #followthescience
-
Regeneron
@Regeneron
In celebration of #womenshistorymonth, @smithsonian launched its #ifthenshecan exhibition, which featured 120 life-size 3D-printed statues of women trailblazers in STEMāincluding four #regeneronsts and #regeneronisef alumni. Learn more: www.si.edu/womensfutures
Smithsonian
@smithsonian
Celebrate #womensfuturesmonth with us and our @SmithsonianAIB, @NMNH @airandspace and @SIGardens with programs and activities, March 5-27. Learn about statue locations and more: www.si.edu/womensfutures #ifthenshecan
-
Regeneron
@Regeneron
We use our unique knowledge and expertise for the benefit of society, the economy and the environment. This #worldhealthday learn more about our 5-year responsibility strategy to help improve our health, planet and community.
-
Regeneron
@Regeneron
#breaking: The European Commission (EC) has approved our medicine for children aged 6 to 11 years with severe #asthma with type 2 inflammation, bringing this first-of-its-kind treatment to younger children. Read more. @Sanofi
-
Regeneron reposted
Society for Science
@Society4Science
"Why wouldnāt you want to volunteer for #regeneronisef? You get to meet people from all over the world, especially the worldās young scientists, mathematicians and robotic engineers!" #nationalvolunteermonth www.societyforscience.org/blog/volunteer-viewpoints-edna-ā¦
-
Regeneron
@Regeneron
This yearās #regeneronsts finalists are accomplished researchers, but did you know they are also working to make the world a better place beyond their science research? Read more: www.societyforscience.org/blog/giving-back-regeneron-sts-ā¦
-
Regeneron
@Regeneron
The U.S. FDA has accepted our sBLA for priority review of our medicine in patients aged 12 years and older with #eoe, a chronic type 2 inflammatory condition that damages the esophagus. Learn more CC: @Sanofi
investor.regeneron.com/news-releases/news-release-details⦠-
Regeneron
@Regeneron
We are so proud of our 2022 #regeneronsts top winner, Christine Ye, and all the (gravitational) waves she has already made in the science community! Check out the latest episode of the @SenecaWomen 100 Women to Hear podcast to learn more about her award-winning research.
-
Regeneron
@Regeneron
We see and hear our transgender colleagues and acknowledge their struggles & bravery. Regeneron believes in equality, freedom and dignity in the workplace & world. We are committed to supporting each other on Trans Day of Visibility & throughout the year. #tdov #betterworkplace
-
Regeneron
@Regeneron
Congratulations to the 2022 #regeneronwesef winners! We love seeing your passion for STEM shine through your stellar projects. Read more: secureservercdn.net/192.169.220.85/uvi.18a.myftpupload.co⦠@WESEFboard
-
Regeneron
@Regeneron
At #aad2022, weāre sharing late-breaking Phase 3 results from a pivotal trial of our medicine in patients with #prurigonodularis. Read the news. @Sanofi
-
Regeneron
@Regeneron
Interested in how medicines are made? Spark that scientific curiosity early with the 2nd annual Pre-Clinical Manufacturing & Process Development (PMPD) High School Rotational Talks. High school students apply here:
-
Regeneron
@Regeneron
Weāre sharing new research at #aad2022 with @Sanofi from more than 20 abstracts in chronic dermatological diseases. New insights span #atopicdermatitis in pediatric and adult patients, as well as #prurigonodularis and #chronicspontaneousurticaria.
-
Regeneron
@Regeneron
Our #iops Raheen team recently brought back its annual 5K run for the first time since 2019. More than 270 colleagues participated while enjoying some friendly competition. Congrats to everyone who participated! Next up, the 2022 Regeneron Great Limerick Run! #rglr2022
-
Regeneron
@Regeneron
Recycling has been key to our business achieving zero waste to landfill and weāre working to further increase our plastics recycling. On #worldrecyclingday, learn how we work to reduce our environmental impact. #responsibleregeneron www.regeneron.com/responsibility/sustainable-communities
-
Regeneron
@Regeneron
Thank you to the #regeneronsts 2022 finalists, @Society4Science and everyone involved for a memorable 2022 competition! āš
Regeneron
@Regeneron
If youāre a rising U.S. high school senior with an outstanding research project, consider applying for next yearās competition. societyforscience.tfaforms.net/64 š
-
Regeneron reposted
Society for Science
@Society4Science
š Congratulations to the 2022 #regeneronsts winners! šwww.societyforscience.org/blog/students-win-1-8-million-aā¦
-
Regeneron
@Regeneron
Congrats to the 2022 #regeneronsts top winner, Christine Ye, for her winning project analyzing the gravitational waves emitted from huge collisions between neutron stars and black holes. We canāt wait to see how these finalists will shape the future of #stem. @Society4Science
-
Regeneron reposted
Society for Science
@Society4Science
We're hours away from announcing the winner of the 2022 #regeneronsts. Join us live as it happens! www.societyforscience.org/regeneron-sts/awards2022/
-
Regeneron
@Regeneron
āYou have the power and responsibility to do something good ā to make a difference.ā ā George Yancopoulos, Prez/CSO and STS alum, spoke with the #regeneronsts finalists on the importance of using their brilliant minds for positive change.
Society for Science
@Society4Science
.@Regeneron Chief Scientific Officer George Yancopoulos chats with the #regeneronsts finalist about his career from Science Talent Search to the founding of Regeneron.
-
Regeneron
@Regeneron
How do we turn #science into medicine? #regeneronsts finalists met with Regeneron scientists from @RegeneronDNA and VelociGene operations to learn how our early-stage and #genetic research informs the medicines we discover, develop and deliver to patients. CC: @Society4Science
-
Regeneron
@Regeneron
Happening now: @Society4Science is live with the #regeneronsts finalists. Head over to Instagram to learn what sparked their love for science (and what TV show theyāre binging right nowā¦): www.instagram.com/society4science/?hl=en
Regeneron
@Regeneron
Then at 2:30 PM ET, donāt forget to tune into the Public Day livestream to learn more about the finalistsā impressive projects which cover 16 different disciplines of science: www.facebook.com/societyforscience #regeneronsts
-
Regeneron
@Regeneron
#regeneronsts is bringing Public Day to you! Join the interactive event tomorrow to learn how this yearās finalists are using #stem to potentially solve societyās most complex challenges: projectboard.world/societyforscience-sts/ CC: @Society4Science
Society for Science
@Society4Science
š Mark your calendars! You won't want to miss this year's virtual #regeneronsts Public Exhibition of Projects! @Regeneron
projectboard.world/societyforscience-sts/coming-soon -
Regeneron
@Regeneron
When did our colleagues realize they wanted to be scientists? Regeneron scientists shared their science journeys and advice for the 2022 #regeneronsts finalists during the Regeneron Innovation Panel. CC: @Society4Science
Post not available here, view on X
Regeneron
@Regeneron
āI now feel much more comfortable being uncomfortable. This is often a very useful angle to bring to research.ā ā Mickey Atwal, VP, Molecular Profiling & Data Science, on how his background has shaped how he thinks about research.
Regeneron
@Regeneron
āTry to break down the problem into smaller parts. Even if thatās making an experiment just to see if one simple ligation happened.ā ā Terrence Turner, Senior Research and Development Specialist, VelociGeneĀ®, on the mindset that drives his work as a scientist.
-
Regeneron
@Regeneron
With @Society4Science, weāre celebrating the 2022 #regeneronsts finalists in DC. Get to know the 40 bright, young scientists who are competing for this yearās top prize: www.societyforscience.org/regeneron-sts/2022-finalists/
Society for Science
@Society4Science
#regeneronsts 2022 officially kicks off! š
@Society4Science President & CEO @MayaAjmera welcomes this yearās finalists.
Regeneron
@Regeneron
Throughout Finalists Week, weāll be recognizing the achievements of this yearās finalists who are working to push the boundaries of science and use their personal drive to positively impact our world.
Regeneron
@Regeneron
To learn more about their innovative research, join us this Sunday (3/13) at the Virtual Public Exhibition of Projects. Tune in here: projectboard.world/societyforscience-sts/
-
Regeneron
@Regeneron
As we push toward the future of medicine, many women like our VP of Research, Lori Morton, are paving a bold path for those in the field. This month follow along as we share more perspectives from women at Regeneron who inspire us to #breakthebias #iwd2022 www.linkedin.com/pulse/modeling-culture-breaks-bias-workpā¦
-
Regeneron
@Regeneron
This week, Regeneron scientists Bola Akinlade, MD, and Lyndon Mitnaul, PhD, of @RegeneronDNA joined @BHMinfo and a panel of experts to discuss how inclusive health research is essential to combating health disparities and advancing science. #betterscience
Regeneron
@Regeneron
Bolaās presentation focused on the importance of clinical trial participation for diverse populations, while Lyndon highlighted how weāre working to facilitate broader representation in genetic research. #betterscience
-
Regeneron
@Regeneron
A recent discovery by @RegeneronDNA shows that COVID-19 risk may be reduced by a mutation in the ACE2 (SARS-CoV-2 receptor) gene. Read more in @NatureGenet.
Regeneron Genetics Center
@RegeneronDNA
Our recent genome-wide analysis shows that levels of the ACE2 receptor influence COVID-19 risk. A genetic variant near the ACE2 gene decreases levels of the SARS-CoV-2 gateway receptor by 37% and infection risk by 40%. Read more about our recent discovery in @NatureGenet.
-
Regeneron
@Regeneron
Congrats to this yearās STEM Research Grant recipients. This Regeneron-supported program will provide funding to 95 teachers committed to advancing #stem education, particularly among underserved and underrepresented communities: www.societyforscience.org/blog/society-for-science-awardsā¦
Society for Science
@Society4Science
We're excited to name this year's STEM Research Grant awardees! www.societyforscience.org/blog/society-for-science-awardsā¦
-
Regeneron
@Regeneron
The March 6 deadline for @Society4Scienceās #societyadvocates program is approaching! If youāre a teacher or mentor supporting underrepresented students with a passion for #stem, consider applying for this initiative, which is supported by Regeneron: advocates.societyforscience.org
Society for Science
@Society4Science
See how our #societyadvocates program is supporting STEM mentors working with underrepresented and low income students. Then apply by March 6! advocates.societyforscience.org
This media couldn't be displayed. See it on the original post. -
Regeneron
@Regeneron
Reminder: Tonight, @BHMinfo is hosting a webinar featuring a panel of Regeneron scientists and health experts discussing the importance of diverse, representative health research to combat health inequities and advance medicine. Register for free here: event.on24.com/eventRegistration/unavailable?&eventid=361ā¦
YWCA White Plains
@YWCAWhitePlains
Join us tonight, March 1st at 6:30PM for this important conversation, "The Importance of Black Lives in Health Studies," sponsored by #regeneron.
Register at event.on24.com/eventRegistration/unavailable?&eventid=361ā¦. -
Regeneron
@Regeneron
Regeneron and @intelliatx announce updated Phase 1 data on the impact of investigational in vivo #crispr therapy on transthyretin (ATTR) amyloidosis disease-causing protein: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
By partnering with patient communities, our scientists can better target health problems and unlock potential solutions. Hear more from our team. #rarediseaseday
Post not available here, view on X
Regeneron
@Regeneron
.@aamdsif, @AELIP_, @TheFHFoundation, @fhpatienteurope, @GlobalGenes, @hemophiliafed, @ifopa, @healourskin, @lipodystrophyuk, @lipodystrophylu
Regeneron
@Regeneron
.@myastheniaorg, @NHF_Hemophilia, @RareDiseases, @pnhcanada, @PNHSupport, @CoalitionHemoB, @wfhemophilia, @worldheartfed, @IADPO, @EveryLifeOrg, @ACCinTouch
-
Regeneron
@Regeneron
With @Sanofi, weāre presenting positive late-breaking data for our medicine in eosinophilic esophagitis (EoE), a chronic type 2 inflammatory disease that can impact a personās ability to eat. #aaaai22
-
Regeneron
@Regeneron
At #aaaai22, weāre presenting late-breaking pivotal data for our medicine in chronic spontaneous urticaria with @Sanofi.
-
Regeneron
@Regeneron
Weāre announcing with @Sanofi that our medicine has been approved in China for children aged 6 to 11 years with uncontrolled moderate-to-severe #atopicdermatitis.
-
Regeneron
@Regeneron
On March 1, we're joining @BHMinfo for a multifaceted discussion on the positive impact of diverse, representative health research on the Black community, health equity and the future of medicine. Register for free here: event.on24.com/eventRegistration/unavailable?&eventid=361ā¦
Black Health Matters
@BHMinfo
Black Health Matters will host a virtual webinar in partnership with Regeneron Pharmaceuticals, Incorporated on March 1, 2022, from 6:30 p.m. ā 8:00 p.m. ET, titled, āYour Life Matters: The Importance of Black Lives in Health Studies.ā Register Now: event.on24.com/eventRegistration/unavailable?&eventid=361ā¦
-
Regeneron
@Regeneron
Good things come in 2s. #twosday
-
Regeneron
@Regeneron
Itās almost #rarediseaseday! On February 28, we will be joining @RareDiseases (NORD) for a day of celebration for the #raredisease community! Learn more at rarediseases.org/rare-disease-day/ #showyourstripes
-
Regeneron
@Regeneron
Join David Sotolongo, Senior Director of Global DEI, next Tuesday (2/22) for a panel discussion focused on race and identity in the workplace, including obstacles faced and tips for resiliency. Register here: share.hsforms.com/1kS2ywdQERH2Xh20h_aBQ_A2ny1v?hss_channeā¦
HACR
@HACRORG
Join us next Tuesday, February 22 at 2pm (ET) for HACR's #webinar, moderated by our @LaYai, as it explores what it's like to be Afro Latino in the #workplace. Sign up! share.hsforms.com/1kS2ywdQERH2Xh20h_aBQ_A2ny1v?hss_channeā¦. #afrolatinos #thepowerofhispanicinclusion⢠Thank you to our sponsors, @PepsiCo @Target
-
Regeneron
@Regeneron
Read an update with @Sanofi on our ongoing Phase 3 program in chronic spontaneous urticaria: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
#icymi: The Regeneron DNA Learning Center (@DNALC) is holding week-long camps throughout the summer for middle and high school students interested in #stem. Register today: summercamps.dnalc.org/regenerondnalc/ š
Regeneron Genetics Center
@RegeneronDNA
Registration is now open for @Regeneron DNA Learning Center (@DNALC) summer camps on our Sleepy Hollow campus! Students entering 6th-12th grade are invited to join experienced instructors in these week-long camps, covering all things DNA. 𧬠Learn more. #regenerondnalc
-
Regeneron
@Regeneron
Today, we kicked off registration for the 2022 Regeneron Great Limerick Run, which takes place this May and is one of Irelandās most popular events that encourages individuals to compete and achieve their personal goals. CC: @RGreatLimRun #rglr2022
Regeneron
@Regeneron
Since 2019, #regeneronireland has proudly been the title sponsor of this event. Learn more and register here: greatlimerickrun.com
-
Regeneron
@Regeneron
We are announcing new Phase 2 data from our trial in wet age-related macular degeneration (#wetamd), a leading cause of vision loss in the U.S. #ophthalmology
-
Regeneron
@Regeneron
The FDA has accepted our medicine for priority review in children aged 6 months to 5 years with uncontrolled moderate-to-severe #atopicdermatitis. Learn more. CC: @Sanofi
-
Regeneron
@Regeneron
Our Q4 2021 earnings call begins this morning at 8:30 AM EST.
-
Regeneron
@Regeneron
CSO/Prez George Yancopoulos speaks with @Society4Science Prez Maya Ajmera about #stem education initiatives like #regeneronsts and #regeneronisef, our scientific efforts and his future outlook: www.sciencenews.org/sponsored/conversations-with-maya-geoā¦
-
Regeneron
@Regeneron
Databases that reflect the full genomic diversity of humanity are best positioned to uncover differences across populations. @RegeneronDNA is building the worldās most diverse genomic database, harnessing the power of diversity to start addressing health challenges of all sizes.
This media couldn't be displayed. See it on the original post. -
Regeneron
@Regeneron
At #aaaai22, weāll share new analyses of our medicine in multiple chronic diseases with underlying type 2 inflammation, as well as late-breaking data in #chronicspontaneousurticaria and #eosinophilicesophagitis. Learn more. @Sanofi
-
Regeneron
@Regeneron
Two years running! Weāve been named again to the #spgsustainable1yearbook for our leadership and commitment to building a more sustainable world. CC: @SPGlobal @SPGSustainable1 #responsibleregeneron
-
Regeneron
@Regeneron
Itās official. Our new global initiative to increase awareness of type 2 inflammation has launched. Discover how this immune response can connect seemingly different people around the world, like Rainer and Joana: www.understandtype2inflammation.com @SanofiGenzyme
-
Regeneron
@Regeneron
#breaking: The CHMP recommends extending the approval of our medicine in the EU as an add-on treatment for children aged 6-11 years with uncontrolled severe #asthma with type 2 inflammation. CC: @Sanofi
-
Regeneron
@Regeneron
Congrats to David Glass, MD, VP of Research, Aging/Age-Related Disorders, and Se Jeong, Senior R&D Specialist, Oncology & Angiogenesis, who were elected as @AAAS Fellows.
Regeneron
@Regeneron
David was honored for his contributions to the field of skeletal muscle biology, while Se was recognized for his leadership in supporting pre-collegiate research.
-
Regeneron
@Regeneron
With @Society4Science, weāre introducing the 2022 #regeneronsts finalists!š These 40 bright, young scientists are using #science and technology to explore solutions to societyās most complex challenges, including #covid19 and climate change.
Regeneron
@Regeneron
Chosen from a highly competitive pool of more than 1,800 applicants, the top 40 contenders join an esteemed group of #regeneronsts alumni, including Nobel Laureates and our Presidents, CEO Len Schleifer and CSO George Yancopoulos.
Regeneron
@Regeneron
Learn more about the 2022 finalists and their outstanding research projects, which span a diverse range of #stem-related subjects from animal and plant sciences to computational biology and bioinformatics: www.societyforscience.org/regeneron-sts/2022-finalists/ š©āš¬šØāš¬
-
Regeneron reposted
Nasdaq Exchange
@NasdaqExchange
We partnered with Invesco to learn how Nasdaq-100 listed Regeneron is leveraging technology to change the world of research and medicine.
-
Regeneron
@Regeneron
The FDA will review the sBLA for our #immunotherapy combined with chemotherapy for the first-line treatment of patients with advanced #nonsmallcelllungcancer (#nsclc). Target action date is Sept. 19, 2022. CC: @Sanofi #lcsm
-
Regeneron
@Regeneron
#breaking: Weāre reporting positive results from a second pivotal trial in #prurigonodularis, a chronic skin disease causing severe itch and skin lesions. Learn more. @Sanofi
-
Regeneron reposted
Society for Science
@Society4Science
Get to know this year's #regeneronsts scholars! www.societyforscience.org/blog/regeneron-sts-2022-scholarā¦
-
Regeneron
@Regeneron
We look forward to seeing how this #rgc collaboration with @ukfuturehealth will advance science and health. š§¬
Regeneron Genetics Center
@RegeneronDNA
As a Founding Industry Member of #ourfuturehealth, we join our collaborators across continents in leveraging world-leading technology and research to better understand our health and the diseases that impact it. Learn more about @ukfuturehealth. www.youtube.com/watch?v=r7G5InXtsjY
-
Regeneron
@Regeneron
We're always inspired by the #regeneronsts students who make the future of #science look very bright! š”š§¬š§Ŗ
Society for Science
@Society4Science
"Their research reveals a group of young people with their fingers on the pulse of the nation."
Thank you, @mwdobie of @NewsDay, for highlighting and celebrating this year's #regeneronsts scholars!
#regeneronsts www.newsday.com/opinion/columnists/michael-dobie/michael-⦠-
Regeneron
@Regeneron
Our #dei vision is focused on a simple truthāwe can and will do better. Smita Pillai, our Chief Diversity, Equity & Inclusion Officer, shares more in the latest #regeneronperspectives.
-
Regeneron
@Regeneron
Our three-ton, state-of-the-art cryo-electron microscope creates 3D atomic images to provide a close-up look at how antibodies work against a virus or tumor. Some images have directly contributed to selecting the therapeutic antibodies we're studying today. #followthescience
-
Regeneron
@Regeneron
Attending #jpm22? Tune into our presentation this morning at 10:30 AM EST.
-
Regeneron
@Regeneron
Today we announced a new collaboration with Ultragenyx to commercialize outside the U.S. our treatment for homozygous familial hypercholesterolemia (#hofh), an ultra-rare inherited condition.
-
Regeneron
@Regeneron
Congrats to the 2022 #regeneronsts scholars! With @Society4Science, weāre recognizing 300 young scientists from around the country for their extraordinary research projects, innovative thinking and promise as #stem leaders to solve the worldās biggest challenges.
-
Regeneron
@Regeneron
Congrats to Bonnie Bassler, PhD, Regeneron Board member and renowned molecular biologist, who was awarded the @MicrobioSoc Prize Medal for her significant contributions in the field of #microbiology. microbiologysociety.org/news/society-news/prize-lecture-wā¦
-
Regeneron
@Regeneron
Viral vectors are reprogrammed viruses to deliver therapeutic genetic material, instead of infections, to target cells. Our scientists create these by replacing the virusā DNA with therapeutic genetic material that can be delivered into cells with faulty genes. #followthescience
-
Regeneron
@Regeneron
At #rad2021, weāre presenting positive Phase 3 data for our medicine in children aged 6 months to 5 years with uncontrolled moderate-to-severe #atopicdermatitis. @Sanofi
-
Regeneron
@Regeneron
We are sharing Phase 1 data from our investigational #bispecific antibody in patients with heavily pre-treated multiple myeloma. #ash21 #mmsm
-
Regeneron
@Regeneron
For years, our researchers have put their passion for science to work by researching potential treatment options for patients. Learn more and meet Dr. Andres Sirulnik, who translates his passion for hematology through his research in blood cancers and disorders. #ash21
-
Regeneron
@Regeneron
#breaking: @NEJM has published pivotal Phase 3 results for our medicine in children 6 to 11 years of age with uncontrolled moderate-to-severe #asthma, one of the most common chronic diseases among children. @Sanofi
-
Regeneron
@Regeneron
We're on a mission to use the power of science to bring new medicines to patients⦠over and over again. This means we #followthescience wherever it leads. Follow along as we visit some of the fascinating places science takes us.
-
Regeneron
@Regeneron
We have been recognized alongside @Roche with the @PharmaScrip 2021 Licensing Deal of the Year for our #covid19 collaboration. Congrats to our team, along with the other finalists!
-
Regeneron
@Regeneron
For our commitment to using our resources and expertise to improve our world, we have been named one of America's Most Responsible Companies of 2022 by @Newsweek. Read more about this recognition: www.newsweek.com/americas-most-responsible-companies-2022
-
Regeneron
@Regeneron
.@PopSci recognized our novel #ebola antiviral medicine with their Best of Whatās New Award. This achievement reflects our teamās rapid response, our #antibody cocktail approach and the international collaboration it took to bring this medicine to patients.
-
Regeneron
@Regeneron
This #thanksgiving, we celebrate our colleagues around the globe who embody our company philosophy of #doingwellbydoinggood. Each day, they dedicate themselves to building a healthier future and giving back to their communities through #regenerond4dg, #givingtuesday and more.
-
Regeneron
@Regeneron
Congrats to our Prez/CEO, Len Schleifer, who has been included on @CityAndStateNYās 2021 Westchester Power 100 list for his leadership and contributions to addressing the ongoing pandemic.
-
Regeneron
@Regeneron
We recently hosted our biennial Ethics & Integrity @ Work Day, where our leaders discussed how they embed ethics and integrity within their own teams. Our SVP and Chief Compliance Officer, Beth Holly, keynoted and moderated the event. #responsibleregeneron
-
Regeneron
@Regeneron
Applications for @Society4Scienceās STEM Research Grants are open! This Regeneron-supported grant program provides support to U.S. middle and high school teachers to further #stem research & education. Apply by December 1: srg.societyforscience.org
Society for Science
@Society4Science
Our STEM Research Grants provide support to Middle and High School teachers engaging their students in authentic scientific research. www.societyforscience.org/outreach-and-equity/stem-researā¦
-
Regeneron reposted
Cold Spring Harbor Laboratory
@CSHL
At the 2021 Double Helix Medals dinner, CSHL highlighted the STEM education advocacy of @mroctober, and the scientific contributions of @Regeneron cofounders Leonard Schleifer and George D. Yancopoulos, & raised a historic $5 mil to support research. www.cshl.edu/16th-annual-double-helix-medals-dinner-raiseā¦
-
Regeneron
@Regeneron
Congrats to our Presidents, CEO Len Schleifer and CSO George Yancopoulos, who are the recipients of @CSHL's Double Helix Medal for their critical contributions to the fight against #covid19.
-
Regeneron
@Regeneron
Thank you to the 4K+ colleagues around the world who made our 5th annual #regenerond4dg a success! This year, Regeneron teams around the world came together to volunteer nearly 12K hours to positively impact almost 150 non-profits and organizations.
-
Regeneron
@Regeneron
Announcing our partnership with @FNIH_Orgās NIMBLE project to advance research for evaluating non-invasive methods of detecting non-alcoholic steatohepatitis and potentially improve diagnosis and treatment of this condition.
Foundation for the National Institutes of Health
@FNIH_Org
FNIH is delighted to welcome @Regeneron and @Amgen to the Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) project. This partnership is evaluating non-invasive ways of detecting NASH to improve diagnosis and treatment.
Learn more at: fnih.org/our-programs/biomarkers-consortium/programs/nimble -
Regeneron
@Regeneron
For the third year, weāve been named to the 2021 #djsi World list of #sustainability leaders. As one of only six biotech companies to be included, this achievement reflects our long-standing commitment to improving our world. #responsibleregeneron
-
Regeneron
@Regeneron
Our antibody cocktail was approved in the EU for the treatment of certain non-hospitalized #covid19 patients and to prevent infection.
-
Regeneron
@Regeneron
Today, the EMAās Committee for Medicinal Products for Human Use recommended EU approval for our antibody cocktail to treat and prevent #covid19.
-
Regeneron reposted
Regeneron Genetics Center
@RegeneronDNA
The @Regeneron DNA Learning Center @DNALC on our Sleepy Hollow campus will soon reopen for field trips! Teachers are invited to attend an open house on Nov. 10 or Nov. 18 to tour the space, hear from educators, and learn about our programs. Proof of vaccination required.
-
Regeneron
@Regeneron
Weāre on a mission to inspire and foster the next generation of scientists by exposing young minds from K-12 to the power of #science and equipping them with the tools they need to succeed. #nationalstemday
Post not available here, view on X
Regeneron
@Regeneron
As the nationās oldest and most prestigious science competition for U.S. high school seniors, #regeneronsts recognizes the best and brightest young scientists who are using science to address some of societyās most complex challenges.
Regeneron
@Regeneron
If youāre a U.S. high school senior with an outstanding research project, consider applying today.š The #regeneronsts 2022 application is open until November 10 at 8 PM ET: sciencetalentsearch.smapply.org CC: @Society4Science
-
Regeneron
@Regeneron
Announcing additional positive results from our clinical trial evaluating a single dose of our investigational antibody cocktail to prevent #covid19 in uninfected people over an 8-month period.
Regeneron
@Regeneron
Our President and CSO George Yancopolous on todayās announcement:
-
Regeneron
@Regeneron
At #ash2021, we will share new and updated data from our hematology program in blood cancers and disorders. #mmsm
-
Regeneron
@Regeneron
Our Q3 earnings presentation begins today at 8:30 AM EDT. Tune in here:
-
Regeneron
@Regeneron
We are among 300 companies to be named by @Forbes as the Worldās Top Female Friendly Companies in 2021. For more on this recognition:
-
Regeneron
@Regeneron
Our Prez/CSO, George Yancopoulos, and our head of infectious disease research, Christos Kyratsous, are the 2021 recipients of the Athenagoras Human Rights Award for their efforts to efficiently and rapidly respond to #covid19.
Regeneron
@Regeneron
Congrats to Dr. Albert Bourla of @pfizer and Dr. Ugur Sahin of @BioNTech_Group who also received this yearās Athenagoras Human Rights recognition for their contributions in the fight against #covid19.
-
Regeneron
@Regeneron
As our fifth annual #regenerond4dg comes to a close, here are some of the ways our colleagues have come together to support the causes they care most about.⤵ļø
For more on D4DG, visit: www.regeneron.com/responsibility/sustainable-communities -
Regeneron
@Regeneron
For our efforts to develop our investigational antibody cocktail for COVID-19, we have been recognized by the @GalienFdn with the #prixgalien 2021 Roy Vagelos Pro Bono Humanum Award for Global Health Equity. Congratulations to our team on this achievement!
-
Regeneron
@Regeneron
Once again, we've been named among the Top Biopharma Employers by @sciencemagazine. This year, we earned top marks for our leadership in innovation, social responsibility and loyal employees. #sctopemployer
Regeneron
@Regeneron
Thanks to our inspiring team for making this honor possible and congrats to our peers who made this yearās list!
-
Regeneron reposted
nychealthy
@nycHealthy
Monoclonal antibody treatments have prevented at least 1,100 hospitalizations and 500 deaths in NYC. Treatment should be given as soon as possible after someone tests positive for #covid19, so it is important to get tested right away if you have symptoms: on.nyc.gov/antibody-treatment
-
Regeneron
@Regeneron
After two consecutive virtual competitions, 2020 and 2021 #regeneronsts finalists had the opportunity to meet in person to celebrate their achievements. During the retreat, they were also surpised by a special guest: @EricLander46, 1974 STS alum and White House Science Advisor.
-
Regeneron
@Regeneron
#breaking: Weāre announcing positive topline results from a pivotal trial for our medicine with @Sanofi in people with #eosinophilicesophagitis, a chronic type 2 inflammatory disease that can impact a personās ability to eat. Learn more.
-
Regeneron
@Regeneron
#breaking: Weāre announcing topline Phase 3 results of our medicine in #prurigonodularis, a chronic inflammatory skin disease. Learn more. @Sanofi
-
Regeneron
@Regeneron
At Regeneron, our āwhyā is to pioneer discovery. Be part of the future of genomics by joining the Regeneron Genetics Center (#rgc). Learn more by visiting the recruitment page:
Regeneron Genetics Center
@RegeneronDNA
At #ashg21 we shared our ongoing commitment to drive diversity far beyond genomic data. Just as our genetic diversity expands, so does our team. Hear a bit from our colleagues on their āwhy RGC.ā Apply to find your why: careers.regeneron.com/en/
-
Regeneron
@Regeneron
#breaking: Our medicine with @Sanofi has received FDA approval in certain children aged 6-11 years with uncontrolled moderate-to-severe #asthma.
-
Regeneron
@Regeneron
Congrats to Regeneron Genetics Centerās VP and Chief Genomics and Data Science Officer, @gabecasis on his upcoming presentation on genomic diversity at #ashg21. Sign up to join us at his live talk:
Regeneron Genetics Center
@RegeneronDNA
Want to know how RGCās scientists lead drug discovery and make the impossible, possible? Watch @gabecasis, RGCās VP and Chief Genomics and Data Science Officer tomorrow, at his LIVE Lightening talk on Genomic Diversity #ashg21
-
Regeneron
@Regeneron
Our 5th annual #regenerond4dg kicks off this week! This year, more than 4,000 of our colleagues will participate in 200+ in-person, virtual and remote community service projects that impact 100+ non-profit and community organizations. Here's why they choose to give back:
-
Regeneron
@Regeneron
The Regeneron Genetics Centerās (#rgc) global collaborators help us to uncover data that changes science. Watch below to see how the collaborations inspire discovery.
Regeneron Genetics Center
@RegeneronDNA
We value global collaborations which pioneer discovery. You know what they say, teamwork makes the #gene work š¤. Watch to learn about some of our projects which showcase what #genomicdiversity is all about.
-
Regeneron
@Regeneron
Check out this thought-provoking paper on exome sequencing in @Nature from #rgc and @uk_biobank.
Regeneron Genetics Center
@RegeneronDNA
Read our paper on the exome sequencing of 454,787Ā @uk_biobankĀ participants, published inĀ @Nature. Our scientists continue to push the boundaries of genomics. Their work lights up our genome!
-
Regeneron
@Regeneron
.@aris_baras, SVP and Head of #rgc, reminds us of the power of learning together to move science forward. Follow @RegeneronDNA for more RGC updates.
Regeneron Genetics Center
@RegeneronDNA
āWeāre energized by the best minds & powered by the best data. With innovation at the heart of everything we do, we come together with our number one goal ā how can we move science forward?ā ā Aris Baras, MD, SVP and Head of RGC. Follow for more from RGCās thought-driven leaders!
-
Regeneron
@Regeneron
Our colleague Jeanette Fairhurst and our RisE employee resource group were honored by @mhawestchester for their work to facilitate mental health conversations in the workplace. Drew Murphy, EVP of Research, reflects on their important contributions.
-
Regeneron
@Regeneron
PSA: The Regeneron Genetics Center (#rgc) is now on Twitter! Follow @RegeneronDNA for all things #humangenetics.
-
Regeneron
@Regeneron
In 2020, we worked closely with our colleagues and non-profit partners to reimagine our social impact efforts. Learn how we're creating meaningful change through initiatives like our annual #regenerond4dg which kicks off next week: www.regeneron.com/responsibility/sustainable-communities
-
Regeneron
@Regeneron
The FDA will prioritize review of a BLA for our investigational antibody cocktail for the treatment of non-hospitalized COVID-19 patients and prophylaxis in certain individuals.
Regeneron
@Regeneron
The European Medicines Agency also announced it will review our investigational #covid19 antibody cocktail for use in certain people either as a treatment or as prophylaxis. www.ema.europa.eu/en/news/ema-receives-application-marketā¦
-
Regeneron
@Regeneron
Congrats to our Presidents, CEO Len Schleifer and CSO George Yancopoulos, who are the recipients of @WestchesterBiz's 2021 Westchester Global Leadership Laureate Award for their exceptional leadership and efforts to fight #covid19.
Regeneron
@Regeneron
And a big thank you to our team for their tireless work and making this recognition possible!
-
Regeneron
@Regeneron
This weekend, our Prez/CSO, George Yancopoulos, spoke at @Society4Scienceās High School Research Teachers Conference, a Regeneron-supported event that brings teachers together to share best practices for supporting students in independent #science research.
Society for Science
@Society4Science
"You are the force behind the next generation of scientists." - George Yancopoulos, @Regeneron President and Chief Scientific Officer. #societyteach
-
Regeneron
@Regeneron
Amidst record-breaking entries this year, we have been shortlisted for the @PharmaScrip 2021 COVID-19 Pandemic Special Recognition Award for Clinical Advance of the Year and the Best New Drug of the Year ā non-COVID-19. Way to go, team! pharmaintelligence.informa.com/events/awards/scrip-awardsā¦
-
Regeneron
@Regeneron
We're sponsoring @Base11STEMās virtual #b11nextfrontier Conference & Expo which empowers students and early-career adults to pursue their passion for #stem. Register for this free event to hear from our leaders and scientists on their careers and about career opportunities.
-
Regeneron
@Regeneron
Weāve been named a winner in the Breakthrough/Discovery category of @RE_Pharma Global Pharma Awards for our investigational antibody cocktail for #covid19. Congrats to our team, and also our partners, @Roche, for being a finalist in the Collaboration category.
-
Regeneron
@Regeneron
New #regeneronperspectives: Elizabeth Green, Senior Director, Environment, Health & Safety (EH&S), shares how her team has kept our people and workplace as safe as possible through science-based decision making despite an uncertain new reality.
-
Regeneron reposted
Maya Ajmera
@MayaAjmera
This afternoon from 2-4pm ET, @ScienceNews Editor in Chief @nancyshute and Special Projects Editor @ElizQuill will be on @scifri to talk about a century of science. Tune in! #sn100 www.sciencefriday.com/segments/science-news-100-conversatā¦
-
Regeneron
@Regeneron
We are proud to join @TheFHFoundation and their #race4fh to raise awareness for people living with familial hypercholesterolemia.
Family Heart Foundation
@FamilyHeartFdn
Tomorrow is the last day of the #race4fh & #race4lpa! We're almost at our $100,000 goal. Help us cross the finish line by donating! Together we can save generations of families from #heartdisease & #stroke! #knowfh #knowlpa
give.thefhfoundation.org/2021raceforfhandlpa -
Regeneron
@Regeneron
#covid19 News: Today at @IDWeek2021, weāre sharing positive trial results evaluating our investigational antibody cocktail in patients hospitalized with COVID-19. Read more:
Regeneron
@Regeneron
Our President and CSO discusses todayās announcement:
-
Regeneron
@Regeneron
#covid19 News: @NEJM published positive results from a Phase 3 trial evaluating our investigational antibody cocktail in infected high-risk non-hospitalized COVID-19 patients. Read more:
Regeneron
@Regeneron
Our President and CSO on todayās announcement:
-
Regeneron
@Regeneron
Congrats to our colleagues at @UK_Biobank for launching their new Research Analysis Program. As we say at the Regeneron Genetics Center, "Big data, big opportunities."
UK Biobank
@uk_biobank
Through our new Research Analysis Platform we have made available to approved researchers the exome sequencing data on 300,000 participants. These data help researchers to identify rare genetic variants, which will support the diagnosis, prevention and treatment of diseases.
-
Regeneron
@Regeneron
Congratulations to Dr. Bob Pordy, our Vice President of Cardiovascular & Metabolism Therapeutics, on being honored as a Fellow of @nationallipid. Weāre proud to have him on our team.
National Lipid Association
@nationallipid
The National Lipid Association would like to extend its congratulations to all of our Fellows of the NLA, current and past, honored at the 2021 National Lipid Assocation Honors & Awards Ceremony at #nlasessions
Check out our new Fellows! www.lipid.org/knowledge-center/nla-news/ -
Regeneron
@Regeneron
Congrats to Shohta Ueno, PhD, Director, Dispute Resolution, who was one of 12 lawyers recognized by @ManagingIP in the life sciences sector on this year's Rising Stars Awards EMEA 2021 list. For more: www.managingip.com/article/b1thy8h1v1vsfn/rising-stars-awā¦
-
Regeneron
@Regeneron
The FDA has granted priority review of the sBLA for our investigational #immunotherapy in patients with advanced #cervicalcancer. #gyncsm CC: @Sanofi
Regeneron
@Regeneron
The target action date for the FDA decision is January 30, 2022.
-
Regeneron
@Regeneron
Read how #regeneronisef finalist, Rasha Alqahtani, is helping teens get mental health care. CC: @SmithsonianMag
Smithsonian Magazine
@SmithsonianMag
Rasha Alqahtani, an 18-year-old from Riyadh, Saudi Arabia, won a third award in the behavioral and social sciences category of the Regeneron International Science and Engineering Fair for her prototype of a video game feature to assess anxiety. www.smithsonianmag.com/innovation/teenager-developing-vidā¦
-
Regeneron
@Regeneron
Weāre sharing new analyses of our medicine in uncontrolled moderate-to-severe #atopicdermatitis for people as young as 6 at #wcpd2021 and #eadvcongress. @Sanofi
-
Regeneron
@Regeneron
Today @ #esmo21: Late-breaking positive Phase 3 data for our investigational first-line #immunotherapy combined w/ chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) and varied baseline characteristics. #lcsm CC: @Sanofi
-
Regeneron
@Regeneron
Weāve been named as a finalist in the Breakthrough/Discovery and Collaboration categories of @RE_Pharma Global Pharma Awards for our investigational antibody cocktail for COVID-19. Congratulations to our team, our partners @Roche and the other nominees!
-
Regeneron
@Regeneron
In @SciAmās latest installment of ā18 Minutes Withā¦ā series, our head of oncology Dr. Israel Lowy discusses next-generation cancer #immunotherapies, bispecific antibodies, and how previous research with CD28 superagonists has informed our innovative approach. Watch here:
Scientific American
@sciam
Join us for a new installment of ourĀ Ā #18minuteswith series on next-generationĀ investigational #immunotherapies in oncologyĀ with Dr. Israel Lowy. [Sponsored by @Regeneron]
-
Regeneron
@Regeneron
#covid19 News: @HHSGov and @DeptofDefense will purchase additional doses of our investigational antibody cocktail to meet patient needs.
Regeneron
@Regeneron
Our President and CEO shares more on the news:
Regeneron
@Regeneron
Visit @HHSGov to learn more about #covid-19 antibody therapies and find locations across the U.S. where these treatments may be available: combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antiboā¦
-
Regeneron
@Regeneron
#esmo21: Scroll below for a list of our abstracts at this yearās congress. #skcsm #lcsm #gyncsm #lymsm 1/5
Post not available here, view on X
Regeneron
@Regeneron
Recurrent/metastatic cervical cancer with @Sanofi: 783P #gyncsm 4/5
Regeneron
@Regeneron
Advanced diffuse large B-Cell lymphoma (DLBCL): 839P #lymsm 5/5
-
Regeneron
@Regeneron
This World #atopicdermatitis (AD) Day, weāre announcing the third annual āAgents of Changeā AD Challenge. Weāre calling on people to submit ideas that can help reduce the impact of AD on family life. Learn more about the challenge agentsofchange.hyvecrowd.com/contest/177/overview #changead
-
Regeneron
@Regeneron
š to @EmpireStateDev @GovKathyHochul for launching a new fund to support #newyork academic centers and biotech startups in their critical efforts to combat infectious diseases.
Empire State Development
@EmpireStateDev
Applications are open for the new $40M Biodefense Commercialization Fund!
Grants awarded to startups & academic institutions will help bring to market infectious disease solutionsāand grow New York's expanding #lifescience industry ā¬ļø
www.governor.ny.gov/news/governor-hochul-announces-openin⦠-
Regeneron
@Regeneron
Today, we remember the lives lost and heroic actions of so many on September 11, 2001.
-
Regeneron
@Regeneron
Last year, we achieved our goal to divert 100% of waste from landfill at all Regeneron sites (excluding construction and demolition waste). Learn more about our approach to corporate responsibility: www.regeneron.com/responsibility
#zerowasteweek #responsibleregeneron -
Regeneron
@Regeneron
We have earned the top spot on @Forbesā Best Employers for the state of New York. Thanks to our team who work each day to build a healthier future! www.forbes.com/best-employers-by-state/
-
Regeneron
@Regeneron
Our new educational resource, Now Eye See, provides an in-depth look at how #diabetes can affect #eyehealth, and the path forward that people living with diabetes can take to help protect against vision loss.
-
Regeneron
@Regeneron
At #erscongress, weāre sharing a wealth of data on type 2 inflammation in moderate-to-severe #asthma. @EuroRespSoc @SanofiGenzyme
-
Regeneron
@Regeneron
Stay safe everybody! Weāre thinking of our neighbors in the Hudson Valley and all of you who are affected by severe flooding and power outages due to #hurricaneida.
-
Regeneron
@Regeneron
Our latest research published in @NaturePortfolio aims to provide new insight into the potential use of #celltherapy for #cornealdisease. By understanding the molecular characteristics of corneal cell subtypes, we can help bring innovative new approaches to therapy.
-
Regeneron
@Regeneron
#breaking: Positive topline results from a pivotal Phase 3 trial for our medicine in moderate-to-severe #atopicdermatitis for children as young as 6 months. @Sanofi
-
Regeneron
@Regeneron
Today we announced topline data from a Phase 2 trial investigating a higher dose of our anti-VEGF medicine in patients with #wetamd. Read more: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Get vaccinated! It is the best way to prevent #covid19. But also learn about treatments in case you need them:
combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antibo⦠-
Regeneron
@Regeneron
1) Hi all ā weāre back to share a few more facts about #regeneron and our work to develop a monoclonal antibody treatment for #covid19
Post not available here, view on X
Regeneron
@Regeneron
8) After all the hard work, the most important message we want to share is to please get vaccinated ā but if you get sick and qualify under the FDAās emergency authorization, then get TREATED. Find sites here: protect-public.hhs.gov/pages/therapeutics-distribution
Regeneron
@Regeneron
9) Thanks for reading and for taking a minute to learn more about Regeneron! Here are a few other recent accomplishments ā besides our COVID-19 work ā that we are proud of:
-
Regeneron
@Regeneron
Reminder: Our investigational antibody cocktail for #covid19 is FREE to patients who qualify under the Emergency Use Authorization parameters (just like the vaccines are)
-
Regeneron
@Regeneron
New #covid19 resources are available and regularly being updated to help people find treatment centers. If youāre in CA, MD, MA, MI, MO, TX and WV, check out crushcovid.com.
Regeneron
@Regeneron
You can also visit @HHSgov to learn more about antibody therapies and find locations across the U.S. where these treatments may be available: combatcovid19now.com
Regeneron
@Regeneron
Your state health department or local health systems may also be able to help find treatments available near you.
-
Regeneron
@Regeneron
The latest data on our treatment in #diabeticretinopathy, which emphasizes the importance of proactive treatment, is now published in @JAMAOphth. #ophthalmology
-
Regeneron
@Regeneron
Our Q2 2021 earnings webcast begins this morning at 8:30 AM EDT.
-
Regeneron
@Regeneron
BREAKING: We met the primary endpoint in our Phase 3 trial with @Sanofi, which investigated our immunotherapy with chemotherapy in first-line advanced #nonsmallcelllungcancer (#nsclc) across all PD-L1 expression levels.
Regeneron
@Regeneron
This is our third oncology trial to be stopped early for positive results and the fifth pivotal trial in which our investigational #immunotherapy has demonstrated clinically meaningful benefits.
-
Regeneron
@Regeneron
Today, @NEJM published positive detailed results from a Phase 3 trial assessing the ability of our investigational antibody cocktail to prevent #covid19 infection among household contacts of #sarscov2 infected individuals.
-
Regeneron
@Regeneron
For the third consecutive year, we have been named as one of @FastCompany's Best Workplaces for Innovators thanks to our commitment to fostering a collaborative culture led by #science. #fcbestworkplaces
-
Regeneron
@Regeneron
Congrats to the winners of the 9th annual Regeneron Prize for Creative Innovation, Sergey D. Stavisky of @StanfordMed and Nitsan Goldstein of @Penn, who were recognized for their outstanding research.
Regeneron
@Regeneron
Each year, the country's leading research universities are invited to nominate top candidates for this achievement, which celebrates creativity and independent scientific thinking among postdoctoral fellows and graduate students focused on #biomedical research.
-
Regeneron
@Regeneron
T-cells need two signals to fully activate. But cancer cells can use the PD-1 pathway to inhibit the second signal and suppress T-cell activation. Watch how ā and learn why we are investigating potential combination treatments of a PD- 1 inhibitor and CD28 #bispecifics.
-
Regeneron
@Regeneron
#covid19 News: The FDA authorized our investigational COVID-19 antibody cocktail for emergency use for post-exposure prophylaxis in certain people exposed or at high risk of exposure to a #sarscov2 infected individual because of infection occurring in the same setting.
Regeneron
@Regeneron
The post-exposure prophylaxis extension includes people who are not fully vaccinated or are not expected to mount an adequate response to vaccination. It is not a substitute for a COVID-19 vaccine, and is not authorized for pre-exposure prophylaxis to prevent COVID-19.
Regeneron
@Regeneron
Our President and CSO on why todayās EUA update matters:
-
Regeneron
@Regeneron
#breaking: Positive topline results from a Phase 3 trial for our medicine in chronic spontaneous urticaria, a skin disease resulting in persistent itch and hives. @Sanofi
-
Regeneron
@Regeneron
Today we announce a new collaboration with @AstraZeneca to potentially develop small molecule medicines for obesity based on #rgc discovery of rare genetic mutations in GPR75 gene associated with #obesity protection.
-
Regeneron
@Regeneron
The pandemic served as the ultimate stress test for drug developers. Bari Kowal, SVP, Development Operations & Portfolio Management, shares how she anticipates decentralized methodologies will shape the future of clinical trials. More from @Pharma_Intell: pages.pharmaintelligence.informa.com/embracing-future-of-ā¦
-
Regeneron
@Regeneron
Congrats to the 2021 STEM Action Grant Recipients! This @Society4Science program, supported by Regeneron, provides funding to grassroot organizations that are committed to #stem education for underserved and underrepresented groups. Meet this yearās winners š
Society for Science
@Society4Science
We're awarding $165,000 to 38 creative, community-driven organizations through our STEM Action Grant program. Congratulations to this year's awardees! www.societyforscience.org/press-release/society-for-scienā¦
-
Regeneron
@Regeneron
We have been recognized by the @GalienFdn with two #prixgalien nominees for the 2021 Best Biotechnology Product category. Congratulations to our teams, along with the other finalists!
-
Regeneron
@Regeneron
Our 2025 global responsibility goals focus on addressing the issues that matter most to society and our business. Learn about our progress: www.regeneron.com/responsibility. #responsibleregeneron #esg #csr
-
Regeneron
@Regeneron
Congrats to our Prez/CEO, Len Schleifer, who has been named to @CrainsNewYorkās 2021 Notable in Health Care list for his leadership and commitment to building a healthier future for all.
-
Regeneron reposted
Society for Science
@Society4Science
In the latest episode of @TalkNerdy_Pod, @CaraSantaMaria chats with #regeneronisef winner Michelle Hua and #regeneronsts winner Yunseo Choi. @Regeneron www.carasantamaria.com/podcast/michelle-hua-yunseo-choi
-
Regeneron
@Regeneron
Aris Baras, Head of the Regeneron Genetics Center (#rgc), discusses how rare mutations in GPR75, a gene linked to body weight, may possibly protect against obesity.
Regeneron
@Regeneron
We conducted one of our largest #genomics studies to date, analyzing genetic and health data from more than 645,000 diverse volunteers, and identified a link between the GPR75 gene and body weight. See whatās next: www.regeneron.com/science/genetics-center #rgc
-
Regeneron
@Regeneron
The Regeneron Genetics Center (#rgc) published new findings in @sciencemagazine about the discovery of GPR75 gene mutations that protect against obesity.
-
Regeneron
@Regeneron
In response to the pandemic, @inteGIRLS has engaged nearly 2,000 female and non-binary teens through virtual #stem activities like math competitions and logic puzzles. Learn how @Society4Science's STEM Action Grant Program, supported by Regeneron, helped them to achieve this.
Society for Science
@Society4Science
Since the COVID-19 pandemic, STEM Action Grantee @inteGIRLS pivoted to virtual programming, engaging nearly 2,000 participants from across the country and all over the world. www.societyforscience.org/blog/integirls-engages-female-aā¦
-
Regeneron
@Regeneron
Our novel antiviral #antibody medicine for Zaire ebolavirus was recognized by @RareDiseases at tonightās 2021 #rareimpact Awards. Thanks to our colleagues, along with our collaborators, the healthcare providers and patients, for making this honor possible.
Regeneron
@Regeneron
Our Prez/Chief Scientific Officer, George Yancopoulos, spoke at tonightās ceremony to accept this award on behalf of Regeneron:
-
Regeneron
@Regeneron
Collaboration is key to invaluable genetic research that aids in drug discovery for patients. The #rgc, alongside seven healthcare companies, has led an industry alliance focused on #exome sequencing with data from @uk_biobank. CC: @NatureGenet
-
Regeneron
@Regeneron
Data supporting long-term use of our #atopicdermatitis medicine has been added to our European prescribing label following a positive opinion from the EMAās Committee for Medicinal Products for Human Use. Read more: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Regeneron and @IntelliaTweets announce interim Phase 1 clinical data on impact of investigational #crispr therapy on transthyretin (ATTR) amyloidosis disease-causing protein investor.regeneron.com/news-releases/news-release-detailsā¦
Regeneron
@Regeneron
New clinical data on in vivo CRISPR genome editing in humans presented today @PNSociety1 annual meeting and published in @NEJM
-
Regeneron
@Regeneron
BREAKING: the @EU_Commission approved our immunotherapy in certain adults with advanced #nonsmallcelllungcancer (#nsclc) & advanced #basalcellcarcinoma (#bcc). Read more on the NSCLC approval: investor.regeneron.com/index.php/news-releases/news-relea⦠& the BCC approval: investor.regeneron.com/index.php/news-releases/news-relea⦠CC: @SanofiGenzyme
-
Regeneron
@Regeneron
Today, our Prez/CSO, George Yancopoulos, will be participating in a panel at the @MilkenInstituteās Future of Health Summit to discuss the era of the #genome and data-driven medicine and how these can advance #publichealth.
-
Regeneron
@Regeneron
To commemorate Juneteenth, our colleagues in the Black Employee Resource Group (ERG) hosted a weeklong event with inspiring and educational sessions to spark dialogue and create an opportunity for reflection.
-
Regeneron
@Regeneron
Our SVP, Associate General Counsel and Chief Compliance Officer, Beth Holly, will be moderating a panel during @NYWomensFdn's Women at Work Series. This event features exceptional women across industries and will focus on the ongoing fight for gender and racial equity.
-
Regeneron
@Regeneron
For the fifth consecutive year, we have been named to @PointsofLightās #thecivic50 list of most community-minded companies in the U.S. Learn more:
Regeneron
@Regeneron
This recognition is possible thanks to our colleagues who generously give their time and skills to help advance our shared purpose to make the world healthier. Learn more about our commitment to building sustainable communities: www.regeneron.com/responsibility/sustainable-communities #responsibleregeneron
-
Regeneron
@Regeneron
Our investigational antibody cocktail improved overall survival in hospitalized #covid19 patients who had not mounted their own immune response, in the @UniofOxford RECOVERY trial. Weāll be discussing the data with regulatory authorities.
Regeneron
@Regeneron
Our President and CSO, George Yancopoulos on todayās announcement and next steps for our #covid19 program
-
Regeneron
@Regeneron
Responsible handling of personal data is a key part of succeeding in our mission of turning #sciencetomedicine. Our Chief Privacy Officer, Ericka Watson, introduces our new Data Privacy Philosophy in the latest #regeneronperspectives.
-
Regeneron
@Regeneron
How do we support young scientists working to positively change the world? Three current and former #regeneronsts finalists share their perspectives. CC: @TheAtlantic
-
Regeneron
@Regeneron
Our new research published in @ScienceAdvances uses #machinelearning on complex #singlecell datasets to explore interactions between T cell receptors (TCRs) and their targets ā the molecules that help T cells identify and kill infected or cancerous cells.
Regeneron
@Regeneron
Our computational tools provide a framework for analyzing and predicting TCR-antigen interactions, which helps us better understand the effect of immunotherapies.
-
Regeneron
@Regeneron
The #covid19 pandemic has underlined the need for culturally competent care. Learn how one doctor is applying this practice to help deliver COVID-19 antibody treatments for patients: www.verywellhealth.com/how-aapi-doctors-are-providing-culā¦
-
Regeneron
@Regeneron
Our virtual Annual Meeting of Shareholders begins this morning at 10:30 AM EDT. Tune into the live webcast: www.virtualshareholdermeeting.com/403.html
-
Regeneron
@Regeneron
The Regeneron Genetics Center (RGC) has published new data that shows a protective association between a variant in the SARS-CoV-2 receptor (ACE2) and reduced risk of #covid disease.
-
Regeneron
@Regeneron
Weāre sharing Phase 1 findings on the impact of our investigational agent in patients with relapsed/refractory multiple myeloma (#rrmm) at #eha2021. Read the abstract and tune in on June 11 to learn more: library.ehaweb.org/eha/
-
Regeneron
@Regeneron
Applications for 2022 #regeneronsts are now open! If youāre a rising high school senior with an outstanding research project, make sure to apply by November 10: sciencetalentsearch.smapply.org š¬ š
Society for Science
@Society4Science
Applications for the @RegeneronĀ Science Talent Search 2022 are now open! Apply to the nationās oldest and most prestigious science competition for high school seniors. #regeneronsts sciencetalentsearch.smapply.org
-
Regeneron
@Regeneron
Weāre celebrating #pride all month long. This week, our ReLGBT Employee Interest Group kicked off celebrations by painting an outdoor mural with @loftlgbtcenter in nearby Rye Playland. #pridemonth
-
Regeneron
@Regeneron
Congrats to Stephanie Giordano, R&D Specialist, for being named a 2021 Wunderkind by @914INCBusiness! As the youngest member of our infectious disease rapid response team, she has made critical contributions in progressing our #covid19 efforts. For more: westchestermagazine.com/wunderkinds-home/?sf145200866=1
-
Regeneron
@Regeneron
#covid19 news: The FDA has authorized a lower dose of our investigational antibody cocktail for emergency use. Read more: investor.regeneron.com/news-releases/news-release-detailsā¦
Post not available here, view on X
Regeneron
@Regeneron
This update lowers the dose to half of what was originally authorized, increasing the existing supply.
Regeneron
@Regeneron
Itās also the only antibody therapy currently available in all 50 states, including eight states where emerging variants are of concern.
-
Regeneron
@Regeneron
Congrats to Robert Pordy, VP of Cardiovascular & Metabolism Therapeutics, who was selected for the Fellow of the National Lipid Association (FNLA) Award for his leadership in and contributions to the field of clinical lipidology. CC: @nationallipid
-
Regeneron
@Regeneron
Weāve been named one of the Top #100forhealthyfamilies and #communities by @justcapital_, supported by @RWJF, for using our resources and expertise to make the world a better place. Read on: justcapital.com/news/the-2022-top-100-u-s-companies-suppo⦠#responsibleregeneron
Just Capital
@JustCapital
#covid19, the economic fallout, and #climatecrisis showed the crucial role companies have to play in strengthening the health of communities. See which orgs are leading on key issues in our #100forhealthyfamilies and #communities list, supported by @RWJF.
justcapital.com/news/top-100-u-s-companies-supporting-heaā¦
Regeneron
@Regeneron
This recognition builds on our long-standing commitment to being good citizens and to give back to the communities we serve. Learn more about our responsibility efforts: www.regeneron.com/responsibility/sustainable-communities
-
Regeneron
@Regeneron
During #asco21, weāll be sharing a clinical trial overview for one of our first investigational CD28 costimulatory #bispecific antibodies. Donāt know what CD28 costimulatory bispecifics are or why they have potential in #oncology research? Read on to learn more. š 1/8
Post not available here, view on X
Regeneron
@Regeneron
Understanding this biology led to the development of bispecific #antibodies, an emerging class of antibodies that can use its two binding arms to engage with two different targets at once. 5/8
Regeneron
@Regeneron
Many bispecifics currently under clinical investigation are focused on triggering the first āignitionā signal by binding to the CD3 proteins on T-cells, in addition to a cancer cell protein. At Regeneron, we have several of these in clinical development. 6/8
Regeneron
@Regeneron
We are also taking our research one step further by investigating CD28 costimulatory bispecifics. These are designed to trigger T-cell costimulation by using one arm to bind to a T-cellās CD28 receptor, while the other binds to a cancer protein. 7/8
Regeneron
@Regeneron
Currently, we have several CD28 costimulatory bispecifics in clinical trials ā with more planned. If youād like to learn more about our research, search for TPS5602 at #asco21: meetinglibrary.asco.org 8/8
-
Regeneron
@Regeneron
Congrats to our infectious disease team who are one of this yearās #pm360elite winners in the COVID Heroes category. Learn how they built upon scientific breakthroughs in Ebola and applied those learnings to #covid19: pm360online.com/the-2021-pm360-elite-100/ CC: @PM360online
PM360
@PM360online
We are proud to announce this year's #pm360elite winners. Read all about the incredible achievements of these 100 individuals and teams and the impact they have made on the healthcare and life sciences industry, especially in the past during the pandemic: www.pm360online.com/the-2021-pm360-elite-100/
Regeneron
@Regeneron
After seeing COVID-19 start to spread, our colleagues asked, āHow can we help?ā and worked tirelessly to develop our investigational antibody cocktail for COVID-19. #pm360elite
Regeneron
@Regeneron
Thanks to their diligence, our investigational antibody cocktail went from early-stage research to Emergency Use Authorization in 10 months. #pm360elite
-
Regeneron
@Regeneron
The votes are in, and āQuality of lifeā (QoL) is of most interest. If you agree, check out the poster on QoL in advanced #bcc (9566) from oncologist Dr. Alexander Stratigos, and hear his POV on why research on this topic is valuable in the video below. meetinglibrary.asco.org/browse-meetings/2021 ASCO Annual ā¦
Regeneron
@Regeneron
#asco21 will feature new research on advanced #basalcellcarcinoma (#bcc). Which of the below would be most helpful to learn about?
-
Regeneron
@Regeneron
Thanks to @nyipla for naming our CSO/Pres. George Yancopoulos and VP, infectious disease Christos Kyratsous as Inventors of the Year for their work on #covid19. They are proud to donate their monetary award to @afyafoundation in support of their emergency COVID response efforts.
-
Regeneron
@Regeneron
64.6% of respondents voted for āQuality of lifeā (QoL). If youāre one of them, check out the #asco21 poster on QoL in advanced #nsclc (9078) from oncologist Dr. Mahmut GümüŠand his video below. meetinglibrary.asco.org/browse-meetings/2021 ASCO Annual ā¦
Regeneron
@Regeneron
#asco2021 is expected to provide new insights on advanced #nonsmallcelllungcancer (#nsclc). When it comes to the latest research, which of the below topics interests you the most?
-
Regeneron
@Regeneron
Mental health is vitally important for our overall wellbeing, something our EVP Dan Van Plew hit home as he kicked off the #mentalhealthawarenessmonth āScience of Emotional Intelligence and Self-compassionā event for our colleagues.
-
Regeneron
@Regeneron
We are immensely grateful to all the data contributors taking part in the @GISAID Initiative that enable the unprecedented rapid data sharing in the fight against #covid19.
Regeneron
@Regeneron
We have launched the interactive Regeneron COVID-19 Dashboard, in partnership with @GISAID, to enable scientists and the public to easily monitor the most relevant #sarscov2 variants circulating today. Explore here: covid19dashboard.regeneron.com
-
Regeneron
@Regeneron
JUST IN: The @EMA_Newsās CHMP recommended our #immunotherapy for approval in certain patients with advanced #nonsmallcelllungcancer (#nsclc) and advanced #basalcellcarcinoma (BCC). Read more in our announcement with @SanofiGenzyme: newsroom.regeneron.com/index.php/news-releases/news-releaā¦
-
Regeneron
@Regeneron
Congratulations to all the winners at todayās #regeneronisef Grand Awards Ceremony. Learn more about the top finalists and the work by these young #stem leaders here: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
Donāt miss the #regeneronisef Grand Awards Ceremony at 10 AM EDT. Watch here: x.com/i/broadcasts/1MYxNmPrAZRJw @Society4Science
-
Regeneron
@Regeneron
At todayās symposium, #regeneronisef finalists asked our colleagues questions about their scientific journey, challenges facing biotech amidst #covid19 and more. @Society4Science
-
Regeneron
@Regeneron
Today @NatureGenet published data from the Regeneron Genetics Center #rgc on REGENIE, a new, faster #machinelearning method for genomic sequencing that dramatically reduces computational cost and time of research. go.nature.com/3wl58lL
-
Regeneron
@Regeneron
#asco21 will feature new research on advanced #basalcellcarcinoma (#bcc). Which of the below would be most helpful to learn about?
-
Regeneron
@Regeneron
The #asco21 abstracts are live ā get a preview of what weāre presenting this year: investor.regeneron.com/news-releases/news-release-detailsā¦. Keep scrolling for a handy list of our abstracts by disease area.
Post not available here, view on X
Regeneron
@Regeneron
Cutaneous squamous cell carcinoma (#cscc) abstracts: 9547
#melanoma abstracts: 9515
#ovariancancer abstracts: TPS5602
Regeneron
@Regeneron
Non-small cell lung cancer (#nsclc) abstracts: 9085, 9078, e21091 and e18817
-
Regeneron
@Regeneron
Thank you to the #regeneronisef finalists who stopped by our virtual category receptions to meet our scientists and learn about our #stem work. Weāre looking forward to another busy day tomorrow! @Society4Science
-
Regeneron
@Regeneron
We're focused on exploring ways to help children with uncontrolled #asthma ā a disease with a significant impact on everyday life. Learn more about asthma and type 2 inflammation: www.adventprogram.com/us
-
Regeneron
@Regeneron
Weāre excited to welcome the latest āAgents of Changeā AD Challenge grant recipients. Learn how theyāre helping tackle common challenges of living with AD at: www.changead.com/agentsofchange2020/
-
Regeneron
@Regeneron
#dyk this yearās #regeneronisef features the largest public exhibition of projects to-date? Register now to meet the best young minds in #stem across the world: isef.net @Society4Science
Society for Science
@Society4Science
š The #regeneronisef Public Exhibition of Projects starts now! š Log in to chat with this year's finalists about their research. isef.net
-
Regeneron
@Regeneron
Bispecific #antibody therapies are designed to bind two different molecular targets. Regeneron scientists explain. #aacr21
-
Regeneron
@Regeneron
#asco2021 is expected to provide new insights on advanced #nonsmallcelllungcancer (#nsclc). When it comes to the latest research, which of the below topics interests you the most?
-
Regeneron
@Regeneron
Today at #ats2021, we presented Phase 3 trial results demonstrating the effect of our investigational antibody cocktail in reducing the risk of hospitalization or death in non-hospitalized patients with #covid19: investor.regeneron.com/news-releases/news-release-detailsā¦
Regeneron
@Regeneron
The trial also evaluated the ability of our medicine to shorten symptom duration and reduced viral load in these #covid19 patients.
-
Regeneron
@Regeneron
Weāre announcing new data at #ats2021 that showcase our work with @Sanofi to help improve the care and understanding of moderate-to-severe #asthma for children as young as 6 years of age. Learn more at: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
2021 #regeneronisef begins today! Our President & CSO, George Yancopoulos, spoke during tonightās Opening Ceremony where he highlighted the importance of investing in and supporting todayās #stem talent. CC: @Society4Science
Society for Science
@Society4Science
"This is where we find the science heroes of the future who will lead humanity's fight against so many global threats - from pandemics to climate change right here at #regeneronisef." - George Yancopoulos @Regeneron
-
Regeneron
@Regeneron
Today @TheLancetOncol published pivotal data for our #immunotherapy in locally advanced #basalcellcarcinoma (#bcc). CC: @Sanofi
-
Regeneron
@Regeneron
Join us and @Society4Science as we celebrate the next generation of scientists and engineers during 2021 #regeneronisef from May 16-21! Register here: isef.net
Society for Science
@Society4Science
š We're so excited to share with you this preview of #regeneronisef! It all starts next week. Register today: isef.net
www.youtube.com/watch?v=oUURl06_pVo -
Regeneron
@Regeneron
.@CMSGov recently increased #medicare reimbursement rates for administration of #covid19 antibody treatments, an important update to help support access to COVID-19 care: go.cms.gov/3y9i9AP
-
Regeneron reposted
Society for Science
@Society4Science
Take a look back at all the fun we had at this year's #regeneronsts! Sign up to be the first to know when applications for the 2022 competition open: societyforscience.tfaforms.net/64
This media couldn't be displayed. See it on the original post. -
Regeneron
@Regeneron
Join @AllergyAsthmaHQ with @VinGuptaMD and speakers from @PCORI and @DeptofDefense later today for a discussion on the challenges Black Americans face in managing #asthma and #covid19. allergyasthmanetwork.org/news/asthma-covid-19-and-questioā¦
Allergy & Asthma Network
@AllergyAsthmaHQ
Our final #blackpeoplelikeme virtual event ā āPatient Advocacy in #asthma and #covid19ā ā is May 13! Speakers: @VinGuptaMD, Medical Analyst w/ @MSNBC & @NBC; @DeptofDefense's Lola Williams; patient advisor Mary White; and Rev. Dr. Michael Stinson. allergyasthmanetwork.org/news/asthma-covid-19-and-questioā¦
-
Regeneron
@Regeneron
Today at #esmovirtualplenary, we presented with @Sanofi positive results for our investigational #immunotherapy in advanced #cervicalcancer. Read our press release: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
We have launched the interactive Regeneron COVID-19 Dashboard, in partnership with @GISAID, to enable scientists and the public to easily monitor the most relevant #sarscov2 variants circulating today. Explore here: covid19dashboard.regeneron.com
-
Regeneron
@Regeneron
Our Q1 earnings presentation begins today at 8:30 AM ET. Tune in here: edge.media-server.com/mmc/p/9dtjbq5f
-
Regeneron
@Regeneron
This #worldasthmaday, take time to act. We created the #nextbreathchallenge with @SanofiGenzyme to highlight the importance of demanding better asthma control today. Learn more about the importance of taking action: www.thenextbreath.com/blog/join-the-next-breath-challenge
-
Regeneron
@Regeneron
#icymi: @YWCAWhitePlains recently launched the Westchester Center for Racial Equity, a dedicated space for working towards advancing racial equity in Westchester County. Learn more about this Regeneron-supported initiative: www.ywcawpcw.org
YWCA White Plains
@YWCAWhitePlains
#inthenews . YWCA White Plains & Central Westchester Launches Westchester Center for Racial Equity. More: www.ywcawpcw.org @Regeneron @PepsiCo @MorganStanley @UnitedWayWP @NPWestchester @nyphospital @nostudiosmke
-
Regeneron
@Regeneron
Weāve been named the winner for Pandemic Response for @FastCompanyās World Changing Ideas 2021. A big thank you to our team for their perseverance and incredible efforts during this difficult time to help those in need: www.fastcompany.com/90623897/see-34-ingenious-inspiration⦠#fcworldchangingideas
-
Regeneron
@Regeneron
Good luck to all the students competing at this yearās #regeneronisef! We look forward to celebrating your accomplishments from May 16-21 šš @Society4Science
Society for Science
@Society4Science
ā” Registration for #regeneronisef is now open! ā” Sign up to listen in on distinguished panels of scientists, entrepreneurs and other leaders ā and check out the best high school science projects from all over the world! projectboard.world/isef
-
Regeneron
@Regeneron
At #ats2021, weāll be presenting late-breaking, positive data from trials evaluating two Regeneron medicines. For more: investor.regeneron.com/news-releases/news-release-details⦠@atscommunity
-
Regeneron
@Regeneron
Congrats to our 2021 Regeneron Volunteers of the Year, who led by example and rose to the challenge in 2020 to serve their communities in meaningful and impactful ways. To learn more about our commitment to giving back, visit: www.regeneron.com/responsibility/sustainable-communities?⦠#responsibleregeneron
-
Regeneron
@Regeneron
#dyk the Regeneron Genetics Center (#rgc) has advanced high-throughput sequencing machines and autonomous robots handling DNA samples around the clock? Learn how weāre working to crack the genetic code to find new ways to help address healthās biggest problems. #nationaldnaday
-
Regeneron
@Regeneron
Despite facing an unprecedented public health crisis, we remain focused on using the power of science to combat serious diseases. Read our new Annual Report to learn how we advanced our mission in 2020: investor.regeneron.com/2020AR
Regeneron
@Regeneron
Today, we also released our 2020 Responsibility Report which highlights how we are using our collective expertise, technology and resources to build a healthier future for all. Read on: investor.regeneron.com/2020RR #responsibleregeneron
-
Regeneron
@Regeneron
Weāre committed to turning science into medicine to help people living with serious diseases, including rare conditions like fibrodysplasia ossificans progressiva (FOP). Weāre proud to join in the effort to raise awareness of FOP. CC: @ifopa @RareDiseases @GlobalGenes
-
Regeneron
@Regeneron
Our upcoming data at #aadvmx2021 and #espd2021 showcase our work to improve the care and understanding of uncontrolled moderate-to-severe #atopicdermatitis in people as young as 6. Learn more at: investor.regeneron.com/news-releases/news-release-details⦠@Sanofi
-
Regeneron
@Regeneron
As part of our commitment to protect and restore our planet, we have set ambitious environmental targets, including to go 100% renewable by 2035. Learn how weāre striving to achieve this: www.regeneron.com/responsibility/sustainable-communities #earthday
Regeneron
@Regeneron
Look out for the release of our 2020 Responsibility Report tomorrow for more on how weāre integrating sustainability into our business. #responsibleregeneron
-
Regeneron
@Regeneron
We proudly support the launch of the Westchester Center for Racial Equity ā an important step to combat structural racism and improve opportunity and well-being across communities. CC: @YWCAWhitePlains
-
Regeneron
@Regeneron
#regeneronisef is bringing the best #science and #engineering right into your home. Join us and @Society4Science next month from May 16-21 as we celebrate the next generation of #stem leaders.
Learn more about volunteering at this yearās competition. ā¬ļø
Society for Science
@Society4Science
"You canāt help but come away [from ISEF] feeling uplifted and youāre bound to learn something new!" - past ISEF volunteer
Sign up to volunteer virtually at this year's #regeneronisef! š www.societyforscience.org/isef/volunteers/ -
Regeneron
@Regeneron
As Michigan faces a #covid19 spike, we are working hard to support @migovernment and @GovWhitmerās important efforts for expanding access to monoclonal antibodies. Learn more here: jtv.tv/michigan-expanding-the-use-of-monoclonal-antibody-ā¦
-
Regeneron
@Regeneron
An impressive honor for Dr. Noura Abul-Husn, who received @TheACMG 2021 Dr. Michael S. Watson Genetic and Genomic Medicine Innovation Award. Congrats from your former colleagues and fellow geneticists at Regeneron! šš
ACMG
@TheACMG
ACMG recognizes Noura Abul-Husn, MD, PhD, FACMG @IcahnMountSinai with the 2021 #acmgfoundation for Genetic and Genomic Medicine Dr. Michael S. Watson Genetic and Genomic Medicine Innovation Award. #acmgmtg21 @NouraAbulHusn www.acmg.net/PDFLibrary/WatsonAward2021.pdf
-
Regeneron
@Regeneron
Antibody medicines can help improve #covid19 symptoms and are authorized for use in people who are high-risk for severe disease. If you test positive, have a plan and be ready to act fast. Learn more via @PHEgov: www.phe.gov/emergency/events/COVID19/investigation-MCM/Doā¦
-
Regeneron reposted
Combat COVID
@Combat__COVID
Join @VinGuptaMD and former @US_FDA Commissioner @califf001 tomorrow as they discuss the vital role of monoclonal antibody treatment for high-risk #covid19 patients. #combatcovid #covidtreatments
-
Regeneron
@Regeneron
For high-risk patients, #covid19 antibody therapies may help improve symptoms and reduce risk of hospitalization. Find out more about these therapies and how to locate them from @HHSGov (combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antiboā¦) or @infusioncenter (covid.infusioncenter.org).
-
Regeneron
@Regeneron
For another year, weāve been named to @GPTW_US and @FortuneMagazine's list of #100bestcos! Thank you to our inspiring team, who work tirelessly each day to build a healthier future, for making this recognition possible. Read on: www.greatplacetowork.com/certified-company/1100602?sf1421⦠#bestworkplaces
-
Regeneron
@Regeneron
More #covid19 News: Positive results from a Phase 3 trial in recently infected asymptomatic patients demonstrate the ability of our investigational antibody cocktail to reduce progression to symptomatic #covid19. Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦
Regeneron
@Regeneron
This is the second Phase 3 trial undertaken in collaboration with @NIAIDNews to announce results today. See our earlier announcement here: investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
#covid19 News: Positive results from a Phase 3 prevention trial demonstrate the effect of our investigational antibody cocktail in reducing the risk of symptomatic #sarscov2 infections. CC: @NIAIDNews. Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦
Regeneron
@Regeneron
Additional data in people who still experienced sympomatic infections showed the ability of our #covid19 medicine to clear the virus and reduce symptom duration.
Regeneron
@Regeneron
Our President and CSO, George Yancopoulous on todayās announcement and next steps for our #covid19 program
-
Regeneron
@Regeneron
#covid19 Update: The NIH COVID-19 Treatment Guidelines strongly recommend the use of our investigational antibody cocktail for non-hospitalized #covid19 patients at high risk of clinical progression. Learn more: investor.regeneron.com/news-releases/news-release-detailsā¦
Post not available here, view on X
Regeneron
@Regeneron
The #covid19 guidelines also include details regarding our medicineās response to common variants. Details on its potency against emerging #sarscov2 variants can be found here (Table 2): www.regeneron.com/downloads/regencov-eua-dear-hcp-letter.pdf
Regeneron
@Regeneron
Our President and CEO, Len Schleifer, shares his perspective on todayās announcement, and how it contributes to better supporting #covid19 patients.
-
Regeneron reposted
BARDA
@BARDA
This monthās #bardainnovation Project Spotlight highlights our collaborators at @Regeneron, whose platform technology shortens antibody drug development timelines from yrs to months, generating medicines that fight emerging pathogens & help #savelives. www.medicalcountermeasures.gov/barda/advancing-innovation
-
Regeneron
@Regeneron
The world needs the power of #science, more than ever. On #worldhealthday, we thank all the scientists and healthcare workers who continue to dedicate themselves every day to improving human health.
Regeneron
@Regeneron
Using our unique knowledge and expertise, we remain committed to repeatedly bring new medicines to people with serious diseases. Learn more about our mission: www.regeneron.com/science
-
Regeneron
@Regeneron
If you test positive for #covid19 and are high-risk, there are medicines ā called monoclonal antibodies ā that can help improve symptoms. Learn more about treatment coverage for patients with Medicare, Medicaid and more via @cmsgov: go.cms.gov/2PdRrFd
-
Regeneron
@Regeneron
Our Automated Biobanking Core group is responsible for automated storage and retrieval of biological samples across the company, including the Regeneron Genetics Center #rgc.
Regeneron
@Regeneron
This is one of our biobanks, which makes the task of storing, tracking/managing and retrieving samples, like DNA, more efficient and fully automated. This technology is fully robotic and can handle over 7 million samples with minimal human intervention!
-
Regeneron
@Regeneron
If youāve tested positive for COVID-19 and are high-risk, there are medicines that can help keep you out of the hospital. Talk to a healthcare provider and read more about treatment options via @PHEgov: www.phe.gov/emergency/events/COVID19/investigation-MCM/Doā¦
-
Regeneron
@Regeneron
A new COVID-19 forecasting tool by @NMQF, supported by Regeneron, will equip communities with predictive analytics so they can take action before virus spikes happen. Learn more here: nmqf.org/covid-future-wave-map-tool/
Regeneron
@Regeneron
Explore the preview now: www.thecovidforecast.org #covidforecast
-
Regeneron
@Regeneron
.@JAMAOphth published results from a @NIH sponsored trial showing that people living with diabetic retinopathy had a reduction in vision-threatening complications after two years. investor.regeneron.com/news-releases/news-release-detailsā¦
-
Regeneron
@Regeneron
#dyk that we are the only #biopharma company led by physician-scientists? More than 1K of our full-time employees hold an MD and/or PhD degree. Hereās how we use our collective expertise to turn #science into medicine: www.regeneron.com/about #nationaldoctorsday
-
Regeneron
@Regeneron
#icymi: Yunseo Choi took home the top prize at this yearās #regeneronsts. Hereās a little bit about Yunseo and her āmatching theoryā research that earned her first place.
Society for Science
@Society4Science
For her #regeneronsts project, @PhillipsExeter student Yunseo Choi researched matching theory. The project helped her win first place and $250,000. www.societyforscience.org/press-release/virtual-regeneronā¦
This media couldn't be displayed. See it on the original post. -
Regeneron
@Regeneron
We welcome Boaz Hirshberg, MD, MBA, as our new SVP of Clinical Sciences General Medicine. Boaz will lead work for a broad range of therapeutic areas including ophthalmology, cardiovascular and metabolic, pain and neurology, and infectious and rare diseases.
-
Regeneron
@Regeneron
If youāve tested positive for COVID-19 and are high-risk, there are medicines available that could help reduce the risk of hospitalization. Learn more about treatment coverage for Medicare, Medicaid, ACA exchange and more via @cmsgov: go.cms.gov/2PdRrFd
-
Regeneron
@Regeneron
Congrats to Chiatogu Onyewu, MD, PhD, who was named a 2021 Rising Star by @HBAnet for her leadership within our Research Program Management department and for being a champion for her team and mentees. Learn more: hbanet.org/our-impact/hba-awards/hba-rising-stars/previou⦠#hbawoty21 #hbaimpact
-
Regeneron
@Regeneron
Tune into tonightās @BCAgainstCOVID Making It Plain town hall with @blackdoctor at 7pm ET. Our own Dr. Ernesto Oviedo-Orta, alongside @DrWoodcockFDA, will discuss treatment of #covid19 with minority health professionals at 7:45pm ET. Watch here: www.youtube.com/blackdoctororg?sf140722549=1&cbrd=1&ucbcb=1
-
Regeneron
@Regeneron
#covid19 news: Weāre announcing new positive Phase 3 data demonstrating the effect of our investigational antibody cocktail in reducing risk of hospitalization or death, and duration of symptoms in non-hospitalized patients with COVID-19: investor.regeneron.com/news-releases/news-release-detailsā¦
Regeneron
@Regeneron
Data from a companion virology trial evaluating different doses and administration of our investigational antibody cocktail were also announced.
-
Regeneron
@Regeneron
.@STEMconnector released its 2021 report on The State of Diversity, Equity, & Inclusion in #stem with the mission to achieve a more diverse and sustainable workforce. Learn more: www.stemconnector.com/download-resource/the-state-of-diveā¦
STEMCONNECTOR
@STEMconnector
As part of our commitment to creating greater awareness and adoption for DEI in STEM, we are releasing our latest research report titled: āThe State of Diversity, Equity, & Inclusion in STEM: 2021ā
www.stemconnector.com/download-resource/the-state-of-dive⦠#diversityinstem #diversityinclusionequity -
Regeneron
@Regeneron
From machine learning to a biochar filtration system to matching algorithms, this yearās #regeneronsts winners are making the future of #science look very bright! Learn more about their impressive research via @Forbes: www.forbes.com/sites/kevinanderton/2021/03/18/the-winners⦠CC: @Society4Science
-
Regeneron
@Regeneron
Looking for #covid19 antibody therapies? Visit @HHSGov (combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antiboā¦) or @infusioncenter (covid.infusioncenter.org?sf140551658=1) to find information about these treatments and treatment centers in your area.
-
Regeneron
@Regeneron
As 2021 #regeneronsts comes to a close, we thank @Society4Science, the finalists and everyone involved for another successful year! āš
Regeneron
@Regeneron
If youāre a rising U.S. high school senior with an outstanding research project, consider applying for next yearās competition. Learn more: societyforscience.tfaforms.net/64 š
-
Regeneron
@Regeneron
We stand with the Asian community. #stopasianhate
-
Regeneron
@Regeneron
Congrats to the 2021 #regeneronsts top winner, Yunseo Choi, for her exceptional research on matching algorithms. We canāt wait to see how she will shape the future of #stem, along with the other finalists! For more: investor.regeneron.com/news-releases/news-release-details⦠CC: @Society4Science šš
-
Regeneron
@Regeneron
During tonightās #regeneronsts awards ceremony, our Prez/CSO and STS alum, George Yancopoulos, discussed the importance of inspiring a new and needed generation of scientific leaders. ā
Regeneron
@Regeneron
āAll the #regeneronsts finalists here today are poised to be the scientific heroes of tomorrow. You have the potential to find solutions to the existential threats we face today and the ones of tomorrow.ā ā George Yancopoulos
-
Regeneron
@Regeneron
Donāt miss the #regeneronsts awards ceremony tonight at 8 PM EDT! Watch live here: www.youtube.com/watch?v=JTPS2Dd54Fk CC: @Society4Science
-
Regeneron
@Regeneron
An interest in #science can lead to many career paths! The #regeneronsts finalists are taking virtual field trips throughout Finalists Week to the Regeneron Genetics Center (#rgc), @MontereyAq, @bermaninstitute and more to learn how science can be applied to various fields.
-
Regeneron
@Regeneron
This yearās finalists join an esteemed group of #regeneronsts alumni, including our PresidentsāCEO Len Schleifer and CSO George Yancopoulos. Join us tomorrow at 8 PM EDT for the awards ceremony to see who takes home the top prize! ssp.6connex.com/event/virtual/vsts/login?mcc=social CC: @Society4Science
-
Regeneron
@Regeneron
Tune into our presentation this morning at the @Oppenheimer 31st Annual Healthcare Conference: wsw.com/webcast/oppenheimer9/register.aspx?conf=oppenheimā¦
-
Regeneron
@Regeneron
Today, our colleagues discussed their work at Regeneron and shared advice with the 2021 #regeneronsts finalists during the Innovation Panel moderated by @halamirza. CC: @Society4Science
Society for Science
@Society4Science
This afternoon, the #regeneronsts finalists got a chance to hear from @Regeneron scientists and learn more about their STEM journeys!
Post not available here, view on X
Regeneron
@Regeneron
"Continue to stay excited about the things you care about, and youāll find your way.ā ā Stephanie Giordano, R&D Specialist, on her advice for #regeneronsts finalists.
Regeneron
@Regeneron
"Follow your heart, and you will find the role and where you need to be.ā ā Michelle LaFond, Exec Dir, Bioreactor Scale-Up & Process Data Enablement, shares words of encouragement for the 40 bright, young scientists.
-
Regeneron
@Regeneron
The @AmDiabetesAssn #focusondiabetes campaign is encouraging people living with diabetes-related eye disease to share their story with the goal of helping and inspiring others. Learn more about this initiative which is supported by Regeneron.
American Diabetes Association
@AmDiabetesAssn
Have you been affected by #diabetes and #eyehealth issues? If so, youāre not alone! Sign up to become a #focusondiabetes Champion and share your story to help educate and encourage others here: eyehealth.diabetes.org/become-a-champion.html
-
Regeneron
@Regeneron
The #regeneronsts finalists arenāt always heads down in their research projects. Throughout the week, weāll be highlighting areas where they excel beyond #stem. CC: @Society4Science
Regeneron
@Regeneron
In addition to being multilingual, about 48% of #regeneronsts finalists also have some impressive musical abilities! šµšŗ
Regeneron
@Regeneron
Outside the lab and classroom, #regeneronsts finalists show off their skills on the court š¾ and the field. ā½
-
Regeneron
@Regeneron
Announcing our Phase 3 trial in advanced #cervicalcancer was stopped early after achieving its primary efficacy endpoint. Todayās milestone is a āfirstā for the cervical cancer community. Learn why: newsroom.regeneron.com/news-releases/news-release-details⦠CC: @Sanofi
Regeneron
@Regeneron
Notably, the trial enrolled patients with advanced #cervicalcancer regardless of PD-L1 expression level.
-
Regeneron
@Regeneron
From clean water š to #covid19 diagnostic imaging š„ļø, the #regeneronsts finalists are working to address some of the biggest challenges facing our society. Join us during Public Day to learn about their innovative research: ssp.6connex.com/event/virtual/vsts/login CC: @Society4Science
-
Regeneron
@Regeneron
#regeneronsts is bringing Public Day to you! Join the interactive event tomorrow to learn how the 40 finalists are using STEM to explore life-changing solutions for societyās most complex challenges: ssp.6connex.com/event/virtual/vsts/login CC: @Society4Science
Society for Science
@Society4Science
Donāt have plans for #piday? How about spending it with the Regeneron Science Talent Search 2021 finalists? #regeneronsts www.societyforscience.org/blog/spend-pi-day-with-40-of-thā¦
-
Regeneron
@Regeneron
Weāre on a mission to inspire and foster the next generation of #scientists through initiatives like #regeneronsts. š©āš¬ šØāš¬ Learn more about our commitment to #stemeducation: www.regeneron.com/responsibility/sts-isef CC: @Society4Science
-
Regeneron
@Regeneron
Yesterday evening, our President and CSO (and #regeneronsts alum), George Yancopoulos, sat down with the 40 finalists for a Q&A moderated by @halamirza. CC: @Society4Science
Regeneron
@Regeneron
āWe believe there is nothing more important than helping the next generation of kids like you realize that you have the ability to change the world.ā ā George Yancopoulos on how #science can pave the way for a healthier future.
-
Regeneron
@Regeneron
Today, @NMQF is hosting a webinar featuring @VinGuptaMD and @MiaKeeys who will be discussing different therapeutic options for #covid19. Register here: events.r20.constantcontact.com/register/eventReg?oeidk=a0ā¦
-
Regeneron
@Regeneron
Thanks to our #regeneronireland colleagues, weāve made @GPTW_Irelandās #bestworkplaces21 list for the fifth consecutive year! Read more: greatplacetowork.ie/certified-organisations/regeneron-ireā¦
Regeneron
@Regeneron
We were also named by @GPTW_Ireland as one of the Best Workplaces for Women in Ireland for a third year in a row. #bww21
Great Place To Work Ireland
@GPTW_Ireland
š @Regeneron is recognised as a Best Workplace for Womenā¢! Congratulations and thank you for going the extra mile for Women! š
Want to know how to be a Best Workplace for Women? š greatplacetowork.ie/best-workplaces/women/2021?hss_channeā¦
#bww21 #bestworkplacesforwomen21 #gptw #greatplacetowork #iwd2021 -
Regeneron
@Regeneron
.@NIHDirector @whitehouseostp weāre thrilled to see your high-level commitment to genetic research that can help pts in need #pminetwork




































































































































































































































































































